Curriculum Vitae
PART I:
General Information
Date Prepared:
August 2015
Name:
Shuji Ogino
Office Address:
Department of Pathology
Brigham and Women’s Hospital
75 Francis St.
Boston, MA 02115
Work Phone:
Fax:
Work E-Mail:
Assistant's E-Mail:
617-632-1972
617-582-8558
shuji_ogino[at]dfci.harvard.edu
[email protected]@dfci.harvard.edu
Place of Birth:
Akashi-City, Japan
Education
1993
2001
MD
PhD
2010
MS
Medicine
University of Tokyo
Pathology and Pathogenesis
University of Tokyo
(Advisor, Masashi Fukayama, MD, PhD)
Epidemiology
Harvard School of Public Health
Postdoctoral Training
07/95-06/97
Resident
Anatomic and Clinical Pathology
07/97-06/99
07/99-06/00
07/00-10/01
Resident
Fellow
Post-doc
Anatomic and Clinical Pathology
Molecular Pathology
Molecular Pathology
(PI, Robert B. Wilson, MD, PhD)
Allegheny General Hospital and
Medical College of Pennsylvania
(currently Drexel University)
Case Western Reserve University
University of Pennsylvania
University of Pennsylvania
Faculty Academic Appointments
11/01-09/04
10/04-06/08
07/08-01/15
07/12-04/15
Instructor
Assistant Professor
Associate Professor
Associate Professor
Pathology
Pathology
Pathology
Epidemiology
02/15-
Professor
Pathology
Harvard Medical School
Harvard Medical School
Harvard Medical School
Harvard T.H. Chan School of Public
Health
Harvard Medical School
Shuji Ogino, MD, PhD
04/15-
Professor
2/6/2016
Epidemiology
Harvard T.H. Chan School of Public
Health
Appointments at Hospitals / Affiliated Institutions
Current
11/0111/01-
Pathologist
Investigator
Pathology
Medical Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute
Other Professional Positions
2004-
Member
2004-
Member
2007-
Associate Member
2007-
Member
Gastrointestinal Malignancies Program, Dana-Farber /
Harvard Cancer Center
Cancer Epidemiology Program, Dana-Farber /
Harvard Cancer Center
Center for Molecular Oncologic Pathology, Dana-Farber
Cancer Institute and Brigham and Women’s Hospital
Alliance for Clinical Trials in Oncology (Cancer and Leukemia
Group B in 2007-2011)
Major Administrative Leadership Positions
Local
2002-2009
2012-
Leader, Pathology Advisory Board for the Nurses’ Health Study, and the Health
Professionals Follow-up Study
Leader, Molecular Pathological Epidemiology (MPE) Working Group
Regional
2009-2015
2015-
Member of Board of Directors, Boston Japanese Researchers Forum
Advisor, Boston Japanese Researchers Forum
International
2002-2006
2013-
Member, Board of Directors, Global Japanese Association for Health Care
Chair, The International Molecular Pathological Epidemiology (MPE) Meeting Series
Committee Service
Local
2010-
Member, Gastrointestinal Cancer Center CRIS/STIP Steering Committee, Dana-Farber
Cancer Institute
Regional
2
Shuji Ogino, MD, PhD
2007-2008
2007-2012
2/6/2016
Advisor, Japanese Researchers’ Academic Network of Greater Boston (JARAN)
Member, Scientific Organizing Committee, International Epigenomics and Sequencing
National and International
2002-2005
2003-2005
2006-2008
2011
2014-
Member, Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Sample
Collection and Handling for Molecular Test Methods
Advisor, Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Human
Tissue Procurement and Use for Diagnostic and Pharmaceutical Research
Member, International Meeting on Clinical and Laboratory Genomic Standards (CLGGS)
Member, National Comprehensive Cancer Network (NCCN) Task Force: Evaluating the
Clinical Utility of Tumor Markers in Oncology
Advisor, the Lower GI Panel of the American Joint Committee on Cancer (AJCC)
Professional Societies
19982000-
20022012-
2014-
United States and Canadian Academy of Pathology (USCAP)
2009-2013
Member, Scientific Abstract Review Board
Association for Molecular Pathology (AMP)
2005-2006
Member, Training and Education Committee
2006-2009
CHAMP Moderator
2006-2009
Member, Publications Committee
2006-2009
Member, Methylation Testing Working Group
2007-2008
Member, Nominating Committee
2008-2011
Member, Membership and Professional Development Committee
2011
Chair-elect, Membership and Professional Development Committee
2011-2012
Member, Mutation Nomenclature Working Group
2012-2013
Chair, Membership Affairs Committee
2012Member, Board of Directors
2013
Chair-elect, Solid Tumor Subdivision
2013Member, Strategic Opportunities Committee
2014Chair, Solid Tumor Subdivision
2014Member, Executive Committee
American Society of Investigative Pathology (ASIP)
Society for Epidemiologic Research (SER)
2013Member, Education and Professional Development Committee
2014
Leader, Meet the Expert Roundtable Session at SER Annual Meeting
2015
Chair, Concurrent Contributor Session at SER Annual Meeting
American Society for Clinical Investigation (ASCI)
Elected Member
Federation of American Societies for Experimental Biology (FASEB)
2014Member, Excellence in Science Award Committee
[Societies in which I am not a current member but I have served as a committee member]
College of American Pathologists (CAP)
2000-2001
Junior Member, Biochemical and Molecular Genetics Resource Committee
2007
Member, Molecular Pathology Committee
2007-2011
Member, Molecular Oncology Committee
American Cancer Society (ACS)
2011Member, Biospecimen Advisory Group
3
Shuji Ogino, MD, PhD
2013
2/6/2016
American Association for Cancer Research (AACR)
Co-Chairperson, 12th Annual AACR Frontiers in Cancer Prevention
Research Meeting
[Joint involvement in 3 societies]
Association for Molecular Pathology (AMP), American Society for Clinical Pathology
(ASCP), and College of American Pathologists (CAP)
2013Member, ASCP/CAP/AMP Molecular Testing for Colorectal Cancer
Biomarkers Advisory Panel
Licensure and Certifications
199319992000200120012003-
Full Medical License, Japan
Full Medical License, Commonwealth of Pennsylvania (currently inactive)
Diplomate in Anatomic Pathology and Clinical Pathology, American Board of Pathology
Diplomate in Molecular Diagnostics, American Board of Clinical Chemistry
Full Medical License, Commonwealth of Massachusetts
Diplomate in Molecular Genetic Pathology, American Board of Pathology
Research Grant Review Committees
2002
2011-2012
National Peer Reviewer Panel
2002
Grant Reviewer Panel
2006
Epidemiology of Cancer (EPIC)
Study Section
2008
Biological Sciences Committee
2011
Study Section: Special Emphasis
Panel for RFA-ES-10-002:
Epigenomics of Human Health and
Diseases
2011
Training & Career Development
Board
2011
Grant Reviewer Board
2012
2011-2012
Grant Evaluation Unit
2006
2008
2011
2011
2011
2012
Arizona Disease Control Research Commission
Ad Hoc Member
Association for International Cancer Research (AICR)
Ad Hoc Member
NIH
Ad Hoc Member
Cancer Research UK
Ad Hoc Reviewer
NIH
Member
Cancer Research UK
Ad Hoc Reviewer
The Netherlands Organisation for Health Research
and Development (ZonMw)
External Refree
European Commission (Research and Development),
European Union (EU)
External Reviewer
Editorial Activities
4
Shuji Ogino, MD, PhD
2/6/2016
Ad Hoc Reviewer (for a total of 162 journals)
Journals with Impact Factor 50 or greater
New England Journal of Medicine
Journals with Impact Factor 20 to 50
JAMA
Lancet
Lancet Oncology
Nature Medicine
Nature Reviews Cancer
Journals with Impact Factor 10 to 20
American Journal of Gastroenterology
American Journal of Human Genetics
European Urology
Gastroenterology
Genome Biology
Gut
Journal of Clinical Oncology
Journal of The National Cancer Institute
Nature Communications
Nature Reviews Clinical Oncology
Nature Reviews Gastroenterology and Hepatology
PLOS Medicine
Progress in Lipid Research
Journals with Impact Factor 5 to 10
American Journal of Clinical Nutrition
Analytical Chemistry
Biochimica et Biophysica Acta-Reviews on Cancer
Cancer Letters
Cancer Research
Carcinogenesis
Clinical Cancer Research
Clinical Chemistry
Clinical Epigenetics
Environmental Health Perspectives
Epidemiology
European Journal of Cancer
Human Mutation
International Journal of Cancer
International Journal of Epidemiology
Journal of Medical Genetics
Journal of Pathology
Molecular Cancer Therapeutics
Modern Pathology
5
Shuji Ogino, MD, PhD
2/6/2016
Molecular Oncology
Mutation Research – Reviews in Mutation Research
Nucleic Acids Research
Oncogene
Oncoimmunology
Oncotarget
PLoS Genetics
Proceedings of the National Academy of Sciences of the USA (PNAS)
Scientific Reports
New Nature title journal
Nature Reviews Disease Primers
Other journals
Pathology
American Journal of Pathology
Analytical and Quantitative Cytology and Histology
Analytical Cellular Pathology
Archives of Pathology and Laboratory Medicine
Diagnostic Molecular Pathology
Disease Markers
Experimental and Molecular Pathology
Expert Review of Molecular Diagnostics
Human Pathology
Journal of Clinical Pathology
Journal of Molecular Diagnostics
Journal of OncoPathology
Pathology – Research and Practice
Pathology Research International
Virchows Archiv
World Journal of Pathology
Molecular Diagnosis and Therapy
Oncology
BMC Cancer
British Journal of Cancer
Cancer
Cancer Biomarkers
Cancer Genetics
Cancer Management and Research
Cancer Medicine
Cancer Prevention Research
Cancer Science
Cancers
Colorectal Cancer
Frontiers in Gastrointestinal Cancers
Frontiers in Oncology
6
Shuji Ogino, MD, PhD
2/6/2016
Future Oncology
Genes, Chromosomes and Cancer
Journal of Cancer Research and Clinical Oncology
Journal of Cancer Research and Experimental Oncology
Molecular Carcinogenesis
Neoplasia
OncoTargets and Therapy
Onkologie
The Oncologist
Translational Gastrointestinal Cancer
World Journal of Gastrointestinal Oncology
Epidemiology / Public Health
Austin Journal of Public Health and Epidemiology
Cancer Causes and Control
Cancer Epidemiology
Cancer Epidemiology, Biomarkers and Prevention
Clinical Epidemiology Reviews
Emerging Themes in Epidemiology
Gastroenterology
BMC Gastroenterology
Expert Review of Gastroenterology and Hepatology
Gastroenterology Research and Practice
ISRN Gastroenterology
Journal of Gastrointestinal and Liver Diseases
World Journal of Gastroenterology
World Journal of Gastrointestinal Pathophysiology
World Journal of Gastrointestinal Endoscopy
World Journal of Hepatology
Medicine
African Journal of Internal Medicine
BMJ Open
Chronic Diseases and Translational Medicine
Journal of Cellular and Molecular Medicine
Journal of Molecular Medicine
Journal of Personalized Medicine
Journal of Postgraduate Medicine
Journal of Translational Medicine
Medical Science Monitor
Molecular Medicine
Personalized Medicine
Pharmacogenomics and Personalized Medicine
Res Medica
World Journal of Diabetes
World Journal of Translational Medicine
7
Shuji Ogino, MD, PhD
2/6/2016
Genomics / Genetics
Annals of Human Genetics
BMC Medical Genetics
BMC Medical Genomics
Clinical Genetics
Cytogenetics and Genomic Research
European Journal of Human Genetics
European Journal of Medical Genetics
Genes
Genomics
Heredity
Journal of Genetics
Molecular Genetics and Metabolism
Pharmacogenomics
Epigenetics / Epigenomics
Epigenetics
Pharmacology
Current Cancer Drug Targets
E3 Journal of Biotechnology and Pharmaceutical Research
Expert Opinion on Biological Therapy
Expert Opinion on Drug Discovery
Expert Opinion on Investigational Drugs
Expert Review of Anticancer Therapy
Pharmacological Research
Microbiology
Infectious Agents and Cancer
Immunology
Clinical and Developmental Immunology
Surgery
Annals of Surgical Oncology
World Journal of Surgical Oncology
Nutrition Science
Nutrition Research
Biology / Biochemistry / Molecular Biology
Analytical Chemistry
Biomolecules
8
Shuji Ogino, MD, PhD
2/6/2016
BioTechniques
DNA and Cell Biology
Journal of Proteomics
Organic Chemistry Insights
Multidisciplinary or Other Fields
Advancements in Genetic Engineering
Archives of Gynecology and Obstetrics
BioMed Research International
EBioMedicine
International Journal of Molecular Sciences
International Journal of Nanomedicine
Journal of Neurology
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis
PLoS ONE
Translational Research
Other Editorial Roles
2003-2004
2005
20072007-2012
20072008
2008200820082008200920092010-2014
201020102010-
Editorial Reviewer
Expert Reviewer
Editor
Editorial Board Member
Editorial Reviewer
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
2011201120112012201220122012201320132014-
Editorial Board Member
Review Editor
Editorial Board Member
Editorial Board Member
Associate Editor
Editorial Board Member
Editorial Board Member
Editorial Board Member
Editorial Board Member
Section Editor (Molecular
Pathological Epidemiology)
Section Editor (Molecular
Pathological Epidemiology)
2014-
Encyclopedia of Medical Genomics and Proteomics
Genetics Home Reference, National Library of Medicine, NIH
Analytical and Quantitative Cytology and Histology
Journal of Molecular Diagnostics
Journal of Postgraduate Medicine
World Journal of Gastroenterology
Clinical Cancer Research
Modern Pathology
Organic Chemistry Insights
World Journal of Gastrointestinal Oncology
The Open Surgical Oncology Journal
Journal of Pathology
ISRN Gastroenterology
International Journal of Clinical and Experimental Pathology
Expert Review of Molecular Diagnostics
World Journal of Gastrointestinal Pharmacology and
Therapeutics
World Journal of Translational Medicine
Frontiers in Gastrointestinal Cancers
American Journal of Pathology
World Journal of Surgical, Medical and Radiation Oncology
World Journal of Pathology
Advancements in Genetic Engineering
Laboratory Investigation
Clinical Epidemiology Reviews
Journal of Cancer Research and Therapeutic Oncology
Annals of Clinical Cytology and Pathology
Austin Journal of Public Health and Epidemiology
9
Shuji Ogino, MD, PhD
2014201420142014-
Section Editor (Molecular
Pathological Epidemiology)
Section Editor (Molecular
Pathological Epidemiology)
Editorial Board Member
Editorial Board Member
2/6/2016
Journal of OncoPathology
Journal of Disease Markers
Gut
British Journal of Cancer
Honors and Prizes
1987-1993
1999
1999
2000
2004
2011
Scholarship
Resident Seminar Competition Finalists Award
Designee for CAP Foundation Scholars Award
Pathologist-in-Training Award
Executive Officer’s Award
Ramzi Cotran Young Investigator Award
2012
2014
Meritorious Service Award
The Best of AACR Journals
2014
2014-
The Most Influential Scientific Minds: 2014
Elected Member
2014-
Elected Member of Excellence in Science Award
Committee
Recipient of R35 Outstanding Investigator Award
(with the best Impact Score of 10)
2015-
The Japan Scholarship Foundation
Ohio Society of Pathologists
College of American Pathologists
Pulmonary Pathology Society
Association for Molecular Pathology
United States and Canadian Academy of
Pathology (USCAP)
Association for Molecular Pathology
American Association for Cancer
Research (AACR)
Thomson Reuters
American Society for Clinical
Investigation (ASCI)
FASEB (Federation of American
Societies for Experimental Biology)
National Cancer Institute
National Institute of Health
10
Shuji Ogino, MD, PhD
2/6/2016
Report of Funded Projects
Funding Information
Past Funded Projects
2001-2012
A Prospective Study of Diet and Cancer
NCI/NIH
P01 CA55075
Co-Investigator (PI, Walter Willett)
This Program Project utilizes the Health Professionals Follow-Up Study and the Nurses'
Health Study, and the hypotheses relate to dietary and hormonal influences, external
carcinogens, physical activity, body mass index, tumor promoting hormonal and growth
factors, and NSAID use.
2001-2006
A Prospective Study of Pancreatic Cancer Pathogenesis
NCI/NIH
R01 CA86102
Co-Investigator (PI, Charles Fuchs)
The purpose of this application was to understand underlying mechanisms, interrelations
among etiologic and pathogenic factors, and specificity in relation to specific tumor markers.
2007-2011
Molecular Epidemiology of Colorectal Cancer
NCI/NIH
K07 CA122826
PI ($138,780; $109,837 in the 4th year; with supplement $50,800 in 2009-2011)
The specific aims are: 1) to examine the relationship between one-carbon nutrients and
epigenetic changes in colorectal cancer; and 2) to examine the relation between energy
balance and related molecular events in tumor as well as patient survival.
2007-2012
Prospective Studies of Diet and Cancer in Men and Women
NCI/NIH
P01 CA055075
Co-Investigator [Other Significant Contributor 2008-2011] (PI, Walter Willett)
This Program Project utilizes the Health Professionals Follow-Up Study and the Nurses'
Health Study, and the hypotheses relate to dietary and hormonal influences, external
carcinogens (including dietary), physical activity, tumor promoting hormonal and growth
factors, and NSAID use.
2007-2013
DF/HCC SPORE in Gastrointestinal Cancer
NCI/NIH
P50 CA127003
Co-Investigator in Tissue and Pathology Core (PI, Charles Fuchs)
The overall aims of this SPORE project are to comprehensively understand carcinogenic
mechanisms of gastrointestinal cancers and to apply novel findings to clinical practice. This
SPORE represents a large multidisciplinary effort encompassing various fields such as cell
biology, oncology, gastroenterology, pathology, radiology, epidemiology and biostatistics.
My role is to analyze molecular and pathologic features of gastrointestinal cancer.
2008-2009
Gene Expression Profiling of Colorectal Cancer in Prospective Cohort Studies
DFCI Friends
Co-PI (PI, Charles Fuchs)
The aim is to conduct genome-wide analysis of gene expression by microarrays in nearly
1000 colorectal cancers identified in the Nurses’ Health Study and Health Professionals
Follow-up Study cohorts.
11
Shuji Ogino, MD, PhD
2/6/2016
2008-2013
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology and Pathogenesis
NCI/NIH
R01 CA124908
Co-Investigator (PI, Charles Fuchs)
This application helps understanding of underlying mechanisms, interrelations among
etiologic and pathogenic factors, variation in response due to genetic susceptibility, and
specificity in relation to specific tumor markers. We can specify recommendations aimed to
reduce its incidence and mortality.
2010-2011
Role of Host Immune Response in Colorectal Cancer
NCI/NIH
P50 CA127003 (DF/HCC SPORE in Gastrointestinal Cancer)
PI for this Developmental Project (Overall PI, Charles Fuchs) $35,000 (direct)
The aims of this GI SPORE Developmental Project are to examine the role of host immune
response in colorectal cancer, to analyze expressions of immunoregulatory molecules in
tumor microenvironment, and to explore genome-wide expression data for the identification
of potential targets for immunotherapy.
2012-2013
Molecular Predictors of Neuroendocrine Tumor Risk and Outcome
Novartis
CRAD001KUS172T
Co-PI (PI, Matthew Kulke)
Our overall aims are to identify clinical, pathological and tumor molecular characteristics of
neuroendocrine tumors which can predict clinical outcome, and to identify risk factors.
2012-2013
Prospective Studies of Diet and Cancer in Men and Women
NCI/NIH
5U19 CA055075
Co-Investigator (PI, Walter Willett)
The purpose of this subcontract to the U19 project is to address hypotheses relate to dietary,
lifestyle and hormonal influences on colorectal neoplasias in the Health Professionals
Follow-Up Study and the Nurses' Health Study.
2013-2014
Role of Gut Microbiota in Colorectal Cancer Development and Progression
DFCI Friends
PI ($23,104)
The aim is to conduct a pilot study of microbial profiling by microbiome sequencing on
paraffin-embedded cancer tissue, for possible application to over 1000 colorectal cancers
identified in the Nurses’ Health Study and Health Professionals Follow-up Study.
2014-2015
Analysis of Host Immunity and Tumor Molecular Characteristics in Colorectal Cancer
NCI/NIH
P50 CA127003 (DF/HCC SPORE in Gastrointestinal Cancer)
PI for Developmental Project (Overall PI, Charles Fuchs) $50,000
The project aims are to analyze expression of immunoregulatory molecules in the tumor
microenvironment, and to explore whole exome sequencing and gene expression profiling
data for the identification of potential targets for immunotherapy.
2015
Obesity-driven PDAC: A Comprehensive Study to Define Mechanisms and New Targets for
Prevention and Therapy
Lustgarten Foundation
Co-Investigator (PI, Charles Fuchs)
This project will run (from January 2015) through December 2017. My effort was removed
due to effort adjustment for NCI R35 Outstanding Investigator Award funding.
12
Shuji Ogino, MD, PhD
2010-2015
2/6/2016
Epigenetic Events and Colorectal Cancer Epidemiology
NCI/NIH
R01 CA151993
PI ($1,821,170)
This grant has been incorporated into NCI R35 CA197735 Outstanding Investigator Award
(project period 8/10/2015 to 7/31/2022). We propose to examine epigenetic changes in
cancer cells in relation to one-carbon nutrients and constitutive loss of imprinting, to shed
lights on epigenetic events during carcinogenic process. In addition, we will utilize
genome-wide mRNA expression data to explore for genes potentially important in altered
one-carbon metabolism and DNA methylation reactions.
Current Funded Projects
2001-2020
Dietary and Hormonal Determinations of Cancer in Women
NCI/NIH
P01 CA087969
Co-Investigator (PI, Graham Colditz 2001-2006, Susan Hankinson 2006-2015, Meir
Stampfer 2015-2020)
The objective of this Program Project, utilizing the Nurses’ Health Study cohort of 121,700
women followed since 1976, is to identify dietary and hormonal determinants of breast,
gastrointestinal, and ovarian cancer risk in women, with the ultimate aim to find means for
prevention and improved survival.
2007-2020
Dietary and Lifestyle Determinants of Colon Cancer Recurrence and Survival
NCI/NIH
R01 CA118553
Co-Investigator (PI, Charles Fuchs)
We propose to utilize a NCI-sponsored adjuvant chemotherapy trial in stage III colon cancer
(CALGB 89803) which provides: 1) longitudinal prospective assessments of diet,
medication, and lifestyle; 2) paraffin-embedded tumor specimens; and 3) comprehensive
data on recurrence, mortality, and chemotherapy toxicity.
2009-2019
Inflammation and Colorectal Neoplasia
NCI/NIH
R01 CA137178
DFCI Subcontract PI (PI, Andrew Chan)
The primary aim of this proposal is to understand the role of inflammation in colorectal
carcinogenic process. Especially, the roles of PTGS2 (cyclooxygenase-2), and
downstream inflammatory mediators will be examined in the Nurses’ Health Study and the
Health Professionals Follow-Up Study.
2010-2015 (currently no-cost extension)
The Influence of Diet and Lifestyle on Patients with Advanced Colorectal Cancer
NCI/NIH
R01 CA149222
Co-Investigator (PI, Jeffrey Meyerhardt)
The aim of this proposal is to examine the role of dietary and lifestyle factors on outcome of
patients with metastatic colorectal cancer who enrolled in clinical trials. My role is to analyze
molecular and pathologic features of metastatic colorectal cancer.
2011-2015 (currently no-cost extension)
Molecular and Genetic Analysis of Neuroendocrine Tumor Risk and Survival
NCI/NIH
R01 CA151532
Co-Investigator (PI, Matthew Kulke)
13
Shuji Ogino, MD, PhD
2/6/2016
The aim of this proposal is to examine etiologies and behavior of neuroendocrine tumors
(carcinoids and pancreatic endocrine tumors). My role is to analyze molecular and
pathologic features of tumors.
2012-2017
Cancer Epidemiology Cohort in Male Health Professionals
NCI/NIH
UM1 CA167552
DFCI Subcontract PI ($755,966) (PI, Walter Willett)
This grant supports the Health Professionals Follow-Up Study. My roles are to manage
pathology laboratory and to provide expertise in tumor tissue analysis and molecular
pathological epidemiology (MPE).
2013-2018
Impact of Celecoxib and Inflammation on Survival in Stage Ill Colon Cancer
NCI/NIH
R01 CA168141
Co-Investigator (PI, Charles Fuchs)
We aim to utilize resource of Alliance trial (CALGB 80702), including a) assessments of diet,
medication usage, and lifestyle; b) tumor specimens; c) blood and germline DNA; and d)
extensive data on cancer recurrence and mortality. My role is to assess tumor molecular
changes and their interactive effects on outcome.
2013-2018
DF/HCC SPORE in Gastrointestinal Cancer
NCI/NIH
P50 CA127003
Co-Director of Tissue and Pathology Core (PI, Charles Fuchs)
The overall aims of this SPORE project are to comprehensively understand carcinogenic
mechanisms of gastrointestinal cancers and to translate novel findings into clinical practice.
This SPORE represents a large multidisciplinary effort encompassing various fields such as
cell biology, oncology, pathology, radiology, epidemiology and biostatistics.
2014-2015
Analysis of Microbiome in Colorectal Cancer
DFCI Friends
PI ($18,000)
The aims are to conduct a pilot study of microbiome analysis on paraffin-embedded
colorectal cancer tissue by 16S rRNA sequencing and PathSeq analysis using whole
exome sequencing (WES) data, and to apply a validated method to over 1500 colorectal
cancers identified in the Nurses’ Health Study and Health Professionals Follow-up Study.
2014-2019
Molecular Pathological Epidemiology of Colorectal Cancer
NCI/NIH
U01 CA137088
DFCI Subcontract PI (PI, Ulrike Peters)
This competitive renewal application is based on a multi-institutional large-scale
consortium, Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). In the
renewal application, molecular pathological epidemiology (MPE) has become a central
theme, to address etiologic heterogeneity of colorectal carcinomas. I will play a major role
as a molecular pathological epidemiologist in this proposal.
2015-2022
Accelerating Transdisciplinary Epidemiology of Colorectal Cancer
NCI/NIH
R35 CA197735
PI ($3,711,193 direct; $6,265,340 total for 7 years)
This R35 Outstand Investigator Award (OIA) application, which received the best Impact
Score of 10, has two broad-term goals. One is to conduct "Molecular Pathological
Epidemiology (MPE)" of tumor molecular pathology, omics, microbiota, immunity and
intratumor heterogeneity, in relation to diet, lifestyle and environmental exposures, and
14
Shuji Ogino, MD, PhD
2/6/2016
clinical outcome. We utilize the resources of the Nurses' Health Study (NHS), NHS II, and
the Health Professionals Follow-up Study. For the second goal to accelerate
transdisciplinary MPE, I plan to develop new statistical methodologies, organize the
International Molecular Pathological Epidemiology (MPE) Meeting Series (to develop
STROBE-MPE guideline), and explore new frontiers in integrative population science such
as "immuno-MPE", "pharmaco-MPE", "social-MPE", "lifecourse-MPE", "causal
inference-MPE", and "MPE-health communication research".
Pending grant
2015-2016 (anticipated)
The Third International Molecular Pathological Epidemiology (MPE) Meeting
NCI/NIH
R13 CA203287
This R13 meeting grant application has received Impact Score of 20, and Council review is
pending.
Report of Local Teaching and Training
Teaching of Students in Courses
Teaching prior to start of current Harvard appointment
1997-1999
Pathology Laboratory Course
Second year medical students
Case Western Reserve University
3-hour session/day for 14 days/year
1997-1998
Pathologic Basis of Diseases
Second year medical students
Case Western Reserve University
3-hour session/day for 5 days/year
1997-1998
Renal Pathology
Second year medical students
Case Western Reserve University
3-hour session/day for 3 days/year
1997-1998
Infectious Diseases
Second year medical students
Case Western Reserve University
3-hour session/day for 5 days/year
1998-1999
Pulmonary Pathology
Second year medical students
Case Western Reserve University
3-hour session/day for 3 days/year
Teaching during current Harvard appointment
2003-2004
HST030 Human Pathology Laboratory
Second year medical students
Harvard Medical School
2-hour session/day for 7 days/year
2011
HST030 Human Pathology Laboratory
Second year medical students
Harvard Medical School
1-hour session/day for 15 days/year
2011
Nutritional Epidemiology of Cancer
Doctoral and Master students (ID510)
Harvard School of Public Health
2-hour lecture
15
Shuji Ogino, MD, PhD
2/6/2016
2012
HST030 Human Pathology Laboratory
Second year medical students
Harvard Medical School
1-hour session/day for 5 days/year
2013
Nutritional Epidemiology of Cancer
Doctoral and Master students (ID510)
Harvard School of Public Health
2-hour lecture
Formal Teaching of Residents, Clinical Fellows and Research Fellows
Teaching during current Harvard appointment
2002-2003
Genetic Risk Analysis
Molecular Genetic Pathology Fellows
Brigham and Women's Hospital
2-hour session/year
2003-2010
Genetic Risk Assessment Workshop
Genetics and Pathology Residents/Fellows
Brigham and Women's Hospital
2-hour session/day for 2 days/year
2003-2011
Advanced Genetic Risk Assessment
Genetics and Pathology Residents/Fellows
Brigham and Women's Hospital
1-hour lecture/year
2010-
Molecular Diagnostics Lecture Series
Pathology Residents/Fellows
Brigham and Women's Hospital
1-hour lecture/year
Clinical Supervisory and Training Responsibilities
Teaching prior to start of current Harvard appointment
1996-1997
Supervision of junior residents /
Allegheny General Hospital
200 hours/year
1997-1999
Supervision of junior residents /
Case Western Reserve University
200 hours/year
1999-2000
Supervision of pathology residents and medical
students in Molecular Pathology Laboratory /
University of Pennsylvania
800 hours/year
2000-2001
Supervision of fellows, residents and medical
students in Molecular Pathology Laboratory /
University of Pennsylvania
100 hours/year
Teaching during current Harvard appointment
2001-2007
Supervision of residents in general surgical
pathology / Brigham and Women’s Hospital
450 hours/year
2004-
Supervision of residents and fellows in molecular
diagnostics / Brigham and Women’s Hospital
300 hours/year
16
Shuji Ogino, MD, PhD
2/6/2016
Laboratory and Other Research Supervisory and Training Responsibilities
2002-
Supervision of research fellows /
Dana-Farber Cancer Institute
Daily mentorship for 11 years
Formally Supervised Trainees (publication data are based on up to the 157th original article)
2001-2002
Ruliang Xu, MD, PhD / Associate Professor of Pathology, New York University
He published one paper as the first author under my supervision.
2002-2003
Chong Xu, MD / Former Instructor in Obstetrics and Gynecology, Harvard Medical School
2005-2006
Taiki Yamaji, MD, MPH / Staff Scientist, National Cancer Center, Japan
2003-2007
Takako Kawasaki, MD, PhD / Physician, Singapore
She published 5 original papers as the first author and 2 other original papers as a co-first
author under my supervision.
2006-2008
Mutsuko Ohnishi, MD / Postdoctoral Fellow, Harvard School of Dental Medicine
She received a fellowship grant (2007-2008) from Japanese Society for Multidisciplinary
Treatment of Cancer, and published 2 original papers as a co-first author under my
supervision.
2006-2008
Aditi Hazra, PhD, MPH / Assistant Professor of Medicine, Harvard Medical School
She received 2008 American Association of Cancer Research Scholar-in-Training Award
under my supervision.
2007-2010
Katsuhiko Nosho, MD, PhD / Assistant Professor of Medicine, Sapporo Medical University
He received a fellowship grant (2008-2010) from Japan Society for Promotion of Science,
and published 8 original papers as the first author and 17 other original papers as a co-first
author under my supervision.
2008-2009
Shoko Kure, MD / Resident in Pathology, Japan Medical University
She published 1 original paper as the first author, and 3 other original papers as a co-first
author under my supervision.
2008-2009
Natsumi Irahara, PhD / Senior Medical Science Liaison Specialist, MSD (Merck)
She published 2 original paper as the first author, and 4 other original papers as a co-first
author under my supervision.
2008-2010
Yoshifumi Baba, MD, PhD / Assistant Professor of Surgery, Kumamoto University
He received a fellowship grant (2009-2010) from Uehara Memorial Foundation, and
published 8 original papers as the first author and 10 other original papers as a co-first
author under my supervision.
2008-2011
Kaori Shima, DDS, PhD / Assistant Professor, Kagoshima University
She published 3 original papers as the first author and 12 other original papers as a co-first
author under my supervision.
17
Shuji Ogino, MD, PhD
2/6/2016
2009-2010
Noriko (Yamaguchi) Tanaka, PhD / Chief, Division of Biostatistics, National Center for
Global Health and Medicine, Japan
She published 1 original paper as the first author and 3 other original papers as a co-first
author under my supervision.
2009-2013
Kimmie Ng, MD, MPH / Assistant Professor of Medicine, Dana-Farber Cancer Institute
I serve as a consultant and advisor for her K07 entitled "Role of Vitamin D, Inflammation,
and Energy Balance in Colorectal Cancer Survival" (K07 CA148894. 7/19/11-6/30/16).
2010-2013
Levi Waldron, PhD / Assistant Professor, City University of New York
He published one original paper as the first author under my supervision.
2010-2011
Jing Xie, MD, MS / Doctoral Student, Harvard School of Public Health
2010
Maiko Suzuki, DDS, PhD / Research Fellow, Forsyth Institute
2010-2014
Mai Yamauchi, PhD / Assistant Professor, University of Tokyo
She published 2 original paper as the first author, and 4 other original papers as a co-first
author under my supervision.
2010-2012
Teppei Morikawa, MD, PhD / Assistant Professor of Pathology, University of Tokyo
He received a fellowship grant (2010-2011) from Japan Society for Promotion of Science,
and published 7 original papers as the first author (including one in JAMA 2011) and 9 other
original papers as a co-first author, under my supervision.
2010-2013
Aya Kuchiba, PhD / Biostatistician, National Cancer Center, Tokyo
She published 1 original paper as the first author, and 11 other original papers as a co-first
author under my supervision.
2010-2013
Yu Imamura, MD, PhD / Staff Surgeon, Kyushu University
He published 1 original paper as the first author, and 4 other original papers as a co-first
author under my supervision.
2010-2013
Xiaoyun Liao, MD, PhD / Senior Research Scientist, Dana-Farber Cancer Institute
She published 2 original papers as the first author (including one in NEJM 2012), and
published 3 other original papers as a co-first author under my supervision.
2011-
Zhirong Qian, MD, PhD / Instructor in Medicine, Dana-Farber Cancer Institute and Harvard
Medical School
He published 1 original paper as the first author, and 1 other original paper as a co-first
author under my supervision.
2011-
Reiko Nishihara, PhD / Instructor in Medicine, Dana-Farber Cancer Institute, Harvard
Medical School and Harvard T.H. Chan School of Public Health
She has been PI of K07 CA190673 (2014-2019) under my mentorship.
She published 4 original papers as the first author (including one in NEJM 2013, one in
JAMA 2013, and one in Am J Clin Nutr 2014), and 8 other original papers as a co-first
author under my supervision.
2011-
Akihiro Nishi, MD, DrPH / Research Fellow, Yale University and Harvard School of Public
Health
18
Shuji Ogino, MD, PhD
2/6/2016
Under my supervision, he received a fellowship grant from Japan Society for Promotion of
Science (2013-2015).
2011-2012
Paul Lochhead, MBBCh, PhD, MRCP / Clinical Fellow, Massachusetts General Hospital
Under my supervision, he received Frank Knox Memorial Fellowship Grant (2011-2012),
and published 2 original papers as the first author, and 9 other original papers as a co-first
author.
2011-2012
Ruifang Sun, MB / Research Scholar, Xi’an Jiaotong University
Under my supervision, she received a scholarship grant from Chinese Scholarship Council
and National Scholarship for Building High Level University.
2012-
Nadine J McCleary, MD / Instructor in Medicine, Dana-Farber Cancer Institute
2012-2013
Seungyoun Jung, ScD / Research Fellow, Brigham and Women’s Hospital
2012-2015
Kentaro Inamura, MD, PhD / Research Fellow, Dana-Farber Cancer Institute
Under my supervision, he received fellowship grants from Japan Society for Promotion of
Science, and Takashi Tsuruo Memorial Fund.
2012-2013
Chen (Cindy) Wu, MD, PhD / Former Research Fellow, Harvard School of Public Health
2013-2014
Sung Kwan Shin, MD, PhD / Research Fellow, Dana-Farber Cancer Institute
2013-
Kathryn Fitzgerald, MS / Doctoral Student, Harvard T.H. Chan School of Public Health
2013-2015
Sun A Kim, MD, PhD / Pathology Resident, National Institute of Health
Under my supervision, she received Early Exchange Postdoctoral Fellowship Grant from
Asan Medical Center, Korea
2013-
Kosuke Mima, MD, PhD / Research Fellow, Dana-Farber Cancer Institute
Under my supervision, he received a fellowship grant from Uehara Memorial Foundation
(2013-2015).
2013-2015
Yasutaka Sukawa, MD, PhD / Staff Physician, Keio University Hospital
Under my supervision, he received Sapporo Hibarigaoka Hospital Postdoctoral Fellowship
Grant for Research Abroad.
2013-
Ting-Ting Li, MD / Research Fellow, Dana-Farber Cancer Institute
2013-
Xuehong Zhang, MD, ScD / Instructor in Medicine, Brigham and Women's Hospital
Under my supervision, he received NIH/NCI R03 award, and K07 award (Calcium and
Colorectal Cancer: Gene-Environment Interactions and Molecular Pathways;
K07CA188126, anticipated from 7/1/15 to 6/30/19)
2013-
Mingyang Song, MD, ScD / Research Fellow, Harvard T.H. Chan School of Public Health
2014-2015
Atsuhiro Masuda, MD, PhD / Assistant Professor, Kobe University
2014-
Juhong Yang, PhD / Research Fellow, Dana-Farber Cancer Institute
19
Shuji Ogino, MD, PhD
2/6/2016
2014-
Ruoxu Dou, MD, PhD / Research Fellow, Dana-Farber Cancer Institute
2014-
Jonathan A. Nowak, MD, PhD / GI Pathology and Molecular Genetic Pathology Fellow,
Brigham and Women's Hospital
Under my supervision, he received Stanley Robbins Research Award in 2015.
2014-
Akiko Hanyuda, MD, MPH / Research Fellow, Harvard T.H. Chan School of Public Health
2015-
Lauren L. Ritterhouse, MD, PhD / Pathology Resident, Brigham and Women's Hospital
2015-
Yin Cao, ScD / Research Fellow, Harvard T.H. Chan School of Public Health
2015-
Yohei Masugi, MD, PhD / Research Fellow, Dana-Farber Cancer Institute
2015-
David A. Drew, PhD / Research Fellow, Massachusetts General Hospital
Formal Teaching of Peers (e.g., CME and other continuing education courses)
1996
Pathology of Endocrine Tumors
Pathology Seminar
Single presentation
Allegheny General Hospital
1998
TGF- Pathway in Disease Pathogenesis
Clinical Pathology Seminar
Single presentation
Case Western Reserve University
1999
ABH and Blood Group Tissue Antigens
Clinical Pathology Seminar
Single presentation
Case Western Reserve University
2000
Spinal Muscular Atrophy Genetic Testing
Department of Pathology Seminar
Single presentation
University of Pennsylvania
2001
PCR and Heteroduplex Formation
Department of Pathology Seminar
Single presentation
University of Pennsylvania
2002-2007
Interesting Case Presentation
Surgical Pathology Update
Three presentations / year
Brigham and Women’s Hospital
2003
Molecular Epidemiology of Colon Cancer
Surgical Pathology Update
Single presentation
Brigham and Women’s Hospital
2007
Molecular Correlates in Colorectal Cancer
Surgical Pathology Update
Single presentation
Brigham and Women’s Hospital
2011
Molecular Pathological Epidemiology: A Great
Opportunity for Pathologists
Surgical Pathology Update
Single presentation
Brigham and Women’s Hospital
Formal Teaching in Degree Programs outside of Harvard
2004-2009
Advanced Genetic Risk Assessment
Brandeis University
Students in Master in Genetic Counseling Program 2-hour session / year
20
Shuji Ogino, MD, PhD
2007-2009
2/6/2016
Advanced Genetic Risk Assessment
Boston University
Students in Master in Genetic Counseling Program 3-hour session / 2 years
Local Invited Presentations
1994
Pathology and Pathogenesis of Adult Respiratory Distress Syndrome / Grand Rounds
The United States Naval Hospital Okinawa, Japan
1997
IGF2 & Related Proteins in Neoplastic/Non-Neoplastic Choroid Plexus / Grand Rounds
Department of Pathology, Case Western Reserve University
2005
Molecular Epidemiology and Outcomes of Colorectal Cancer / Research Seminar
Department of Medical Oncology, Dana-Farber Cancer Institute
2006
Epigenetic and Epidemiologic Research on Colorectal Cancer / Research Seminar
Department of Medical Oncology, Dana-Farber Cancer Institute
2007
Molecular Pathologic Epidemiology of Colorectal Cancer / Special Lecture
Harvard School of Public Health Japanese Student Club
2008
Molecular Pathology and Epidemiology of Colorectal Cancer / Invited Lecture
Health Professionals Follow-up Study, Harvard School of Public Health
2008
Molecular Epidemiology of Colorectal Cancer / Invited Lecture
Harvard Biotechnology Club
2009
Molecular Pathologic Epidemiology of Cancer: An Evolving Field / Invited Lecture
Department of Epidemiology, Harvard School of Public Health
2009
Significance of Inflammation and Immune Reaction in Colorectal Cancer / Invited Lecture
Dana-Farber Cancer Institute
2010
Genome-Wide Expression Profiling of Colorectal Cancer / Invited Lecture
Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital
2011
Molecular Pathological Epidemiology (MPE) of Colorectal Cancer / Invited Lecture
Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital
2012
Molecular Pathological Epidemiology (MPE) Adds New Dimension to Nutrition Analysis / Invited
Lecture
Department of Nutrition, Harvard School of Public Health
2012
Molecular Pathological Epidemiology (MPE): Integrated Molecular and Population Science / Invited
Lecture
Department of Epidemiology, Harvard School of Public Health
2012
Molecular Pathological Epidemiology (MPE) for Current and Future Pathology / Grand Rounds
Brigham and Women's Hospital (Harvard / Longwood Combined Pathology Grand Rounds)
21
Shuji Ogino, MD, PhD
2/6/2016
2014
Molecular Pathological Epidemiology (MPE) of Colorectal Cancer / Lecture
Molecular and Cellular Oncology Division Retreat, Dana-Farber Cancer Institute
2014
Molecular Pathological Epidemiology (MPE): Insights into Vitamin D and Cancer Immunity / Invited
Lecture
Department of Nutrition, Harvard School of Public Health
2014
Molecular Pathological Epidemiology (MPE): Opportunities and Insights on Exposome to Cancer
Immunity (Brigham and Women's Hospital Pathology Research Conference)
Report of Regional, National, and International Invited Teaching and Presentations
Regional
2001
Proficiency Testing Program in Genetic Testing / Invited Lecture
Boston Law and Genetics Group Meeting
2002
Risk Assessment in Genetic Testing / Invited Lecture
Boston Law and Genetics Group Meeting
2004
Genetic Testing: An Update and Future Perspectives / Invited Lecture
Boston Japanese Researchers Forum
2006
Molecular Diagnostics in Research and Clinical Practice / Invited Lecture
Wellesley College
2007
Molecular Classification of Colorectal Cancer: An Update / Grand Rounds
Weill Cornell Medical College and New York Presbyterian Hospital
2007
Career Paths in Medical Science and Practice / Invited Lecture
Japanese Researchers Academic Network of Greater Boston
2007
Road to Independent Investigator / Invited Lecture
Japanese Researchers Academic Network of Greater Boston
2008
Career Development in Life Science / Invited Lecture
Japanese Researchers Academic Network of Greater Boston
2010
Large-Scale Genetic and Epigenetic Analyses of Colorectal Cancer / Invited Lecture
Qiagen Symposium Series 2010, Cambridge, MA (Qiagen)
2012
Molecular Pathological Epidemiology of Epigenetics: Integrated Analysis of Etiologic Factors, Host
and Disease / Invited Lecture
Epigenomics, Sequencing and SNiPs Meeting, Boston, MA
2012
Molecular Pathological Epidemiology (MPE) Adds New Dimensions to Nutritional Science / Invited
Lecture
Tufts University USDA Human Nutrition Research Center Retreat
22
Shuji Ogino, MD, PhD
2012
2/6/2016
Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Keynote Lecture
Chinese American Biomedical Association (CABA) Expert Forum and Regulatory Training
Graduation, Boston, MA
National
2006
Molecular Insights into Colorectal Cancer / Grand Rounds
Department of Pathology, Case Western Reserve University
2006
Molecular Classification and Diagnostics of Colorectal Cancer / Invited Lecture
Department of Pathology, Cleveland Clinic Foundation
2006
Molecular Classification of Colorectal Cancer / Grand Rounds
The University of Texas M.D. Anderson Cancer Center
2009
Molecular Epidemiologic Pathology of Colorectal Cancer / Grand Rounds
Department of Pathology, Thomas Jefferson University
2009
Mutation Nomenclature / Invited Lecture
Department of Pathology and Laboratory Medicine, University of Pennsylvania
2009
Colorectal Cancer “Molecular Epidemiologic Pathology” / Invited Lecture
Department of Pathology and Laboratory Medicine, University of Pennsylvania
2011
Molecular Pathological Epidemiology of Cancer: New Research Opportunities / Invited Lecture
Department of Pathology, University of Alabama at Birmingham
2013
Molecular Pathological Epidemiology (MPE): Integrative Analysis of Environment, Host and Cancer
/ Invited Lecture
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH
2014
Molecular Pathological Epidemiology (MPE): Integrative Science to Analyze Host (Immunity),
Environment, and Tumor / Invited Lecture
Center for Cancer Research, National Cancer Institute, NIH
2015 (anticipated) Molecular Pathological Epidemiology (MPE) for Novel Integrative Scientific
Framework, Paradigms and Methods / Invited Lecture
Ichan Medical School of Mount Sinai
International (including lectures at international meetings)
2004
Molecular Epidemiologic Data from Nurses’ Health Study / Invited Lecture
Association for Molecular Pathology Meeting, Los Angeles, CA
2004
Molecular Epidemiology of Colon Cancer / Grand Rounds
Tokai University School of Medicine, Japan
2004
Molecular Diagnostics in the United States / Grand Rounds
Tokai University School of Medicine, Japan
23
Shuji Ogino, MD, PhD
2/6/2016
2004
Genetic Risk Assessment for Genetic Counseling / Grand Rounds
Tokai University School of Medicine, Japan
2004
Molecular Epidemiology of Colon Cancer / Invited Lecture
University of Tokyo School of Medicine, Japan
2004
Molecular Diagnostics in the United States: An Update / Invited Lecture
University of Tokyo School of Medicine, Japan
2004
Diagnostic Molecular Pathology: An Update and Hurdles / Invited Lecture
Keio University School of Medicine, Japan
2004
Molecular Pathology and Epidemiology of Colon Cancer / Invited Lecture
National Cancer Center, Japan
2004
Gene Tests: An Update and Practical Issues / Invited Lecture
Hosei University School of Law, Japan
2004
Molecular Diagnosis: An Overview and Update / Grand Rounds
Tohoku University School of Medicine, Japan
2004
Molecular Pathology and Preventive Medicine / Invited Lecture
Tokyo Medical University, Japan
2005
Bayesian Risk Analysis / Invited Lecture
Association for Molecular Pathology Meeting, Scottsdale, AZ
2006
Postgraduate Training and Risk Management in Pathology / Grand Rounds
Yokohama City University, Japan
2006
Epigenetic Analysis of Colon Cancer / Grand Rounds
Yokohama City University, Japan
2006
Epigenetics of Colorectal Cancer / Invited Seminar
National Cancer Center, Japan
2006
CpG Island Methylator Phenotype of Colon Cancer / Invited Lecture
Kobe University School of Medicine, Japan
2006
Mutation Nomenclature Guidelines / Invited Lecture
Association for Molecular Pathology Meeting, Orlando, FL
2006
Bayesian Genetic Risk Analysis / Invited Lecture
Association for Molecular Pathology Meeting, Orlando, FL
2007
CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer / Invited Lecture
3rd International Quantitative PCR Meeting and Epigenomics Meeting, San Diego, CA
2007
Epigenetic Profiling of Colorectal Cancer / Invited Lecture
Digestive Disease Week (American Gastroenterological Association), Washington, DC
24
Shuji Ogino, MD, PhD
2/6/2016
2007
Epigenetic Profiling of Colorectal Cancer in a Large-Scale Study / Invited Lecture
First International Epigenomics & Sequencing, Boston, MA
2007
Mutation Nomenclature / Invited Lecture
Association for Molecular Pathology Meeting, Los Angeles, CA
2007
Methods of CpG Methylation Testing / Invited Lecture
Association for Molecular Pathology Meeting, Los Angeles, CA
2008
CpG Island Methylator Phenotype (CIMP) / Workshop Panelist
American Association for Cancer Research (AACR) Cancer Epigenetics Meeting, Boston, MA
2008
Significance of Epigenomic Aberrations in Colorectal Cancer / Invited Lecture
Second International Epigenomics and Sequencing , Boston, MA
2008
Epigenetics of Colorectal Cancer / Invited Lecture
Colorectal Cancer Summit, Cleveland, OH
2008
Bayesian Analysis Workshop / Invited Lecture
Association for Molecular Pathology Meeting, Grapevine, TX
2008
LINE-1 Hypomethylation in Colorectal Cancer / Invited Lecture
Association for Molecular Pathology Meeting, Grapevine, TX
2009
Clinical and Pathological Significance of Epigenomic Changes in Colorectal Cancer / Invited
Lecture
United States and Canadian Academy of Pathology (USCAP), Boston, MA
2009
Epigenomics of Colorectal Cancer / Invited Lecture
Third International Epigenomics and Sequencing, Boston, MA
2009
Biostatistics, Epidemiology and Molecular Diagnostics / Workshop Presenter
Association for Molecular Pathology Meeting, Kissimmee, FL
2009
Molecular Classification and Molecular Testing in Colorectal Cancer / Invited Lecture
Association for Molecular Pathology Meeting, Kissimmee, FL
2010
Epigenomic Diversity of Colorectal Cancer / Invited Lecture
Epigenetics World Congress, Boston, MA
2010
Significance of Epigenomic Changes in Colorectal Cancer / Invited Lecture
Maastricht University, The Netherlands
2010
Significance of Genetic and Epigenetic Changes in Colorectal Cancer / Invited Lecture
University of Basel, Switzerland
2010
Epigenetic and Genetic Diversity of Colorectal Cancer / Invited Lecture
Colon Cancer in Murine Models and Humans III, Bar Harbor, ME
2010
Molecular Heterogeneity in Colorectal Neoplasia Pathways / Invited Lecture
25
Shuji Ogino, MD, PhD
2/6/2016
NCI-sponsored Serrated Polyps Consensus Meeting, Cleveland OH
2011
Molecular Pathology of Colorectal Cancer: Deciphering Complex Multifactorial Diseases / Invited
Lecture
US and Canadian Academy of Pathology (USCAP) Annual Meeting, San Antonio, TX
2011
NCI-Funded Cancer Prevention and Control Fellows Workshop / Invited Lecture
American Society of Preventive Oncology Annual Meeting, Las Vegas, NV
2011
Epigenetics of Colorectal Cancer / Invited Lecture
Epigenetics World Congress, Boston, MA
2011
Molecular Pathological Epidemiology of Colorectal Cancer: An Emerging Interdisciplinary Field /
Invited Lecture
International Symposium on Physiology and Diseases of the Digestive Tract, Sherbrooke, Canada
2011
Epigenomics and Molecular Pathological Epidemiology of Colorectal Cancer / Invited Lecture
Forth International Epigenomics and SNPomics, Boston, MA
2011
Mutation Nomenclature: Why Standardize? / Invited Lecture
Association for Molecular Pathology Annual Meeting, Grapevine, TX
2012
Molecular Pathological Epidemiology of Colorectal Cancer for Personalized Medicine / Invited
Lecture
Seoul National University Cancer Hospital 1st Anniversary Symposium, Korea
2012
Molecular Pathological Epidemiology of Colorectal Cancer for Personalized Medicine / Invited
Lecture
Kyoto University, Japan
2012
Molecular Pathological Epidemiology of Lifestyle Factors and Diseases / Invited Lecture
National Hospital Organization Kyoto Medical Center, Japan
2012
Molecular Pathological Epidemiology of Colorectal Cancer / Invited Lecture
Kumamoto University, Japan
2012
Molecular Pathological Epidemiology: Integrated Analysis of Host & Cancer Epigenetics / Invited
Lecture
Epigenetics World Congress, Boston, MA
2012
Molecular Pathological Epidemiology of Epigenetics: Integrated Analysis of Etiologic Factors, Host
and Disease / Invited Lecture
Epigenomics, Sequencing and SNiPs Meeting, Boston, MA
2012
Molecular Pathological Epidemiology (MPE): Novel Integrative Molecular and Population Science /
Invited Lecture
University of Bergen, Norway
2012
Molecular Pathological Epidemiology (MPE): Novel Integrative Pathological Science / Invited
Lecture
Swedish Molecular Pathology Meeting, Uppsala, Sweden
26
Shuji Ogino, MD, PhD
2/6/2016
2012
Molecular Pathological Epidemiology (MPE): Novel Integrative Science for Future Genetics and
Epigenetics / Invited Lecture
Slovak Society of Medical Genetics and Slovak Medical Association 23rd Izakovič Memorial
Meeting, Blatislava, Slovakia
2012
Novel Integrative Science of Molecular Pathological Epidemiology (MPE) of Cancer / Invited
Lecture
Online Webinar
2012
Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Keynote Lecture
Chinese American Biomedical Association (CABA) Expert Forum and Regulatory Training
Graduation, Boston, MA
2013
Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture
RIKEN Quantitative Biology Center, Osaka, Japan
2013
Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture
University of Tokyo Global COE Program Retreat, Oiso, Japan
2013
Molecular Pathological Epidemiology (MPE) of Cancer: Novel Integrative Science / Invited Lecture
National Cancer Center, Tokyo, Japan
2013
Molecular Pathological Epidemiology (MPE): Novel Integrative Science / Invited Lecture
University of Tokyo Institute of Medical Sciences, Tokyo, Japan
2013
Molecular Pathological Epidemiology (MPE) of Cancer: Novel Integrative Science / Invited Lecture
The Japanese Foundation of Cancer Research Institute, Tokyo, Japan
2013
Molecular Pathological Epidemiology (MPE): Integrative Interdisciplinary Science / Lecture
The First International Molecular Pathological Epidemiology (MPE) Meeting, Boston, MA
2013
Molecular Pathological Epidemiology (MPE): Integrated Science of Host & Cancer
Epigenetics / Invited Lecture
Genomics Research Meeting, Boston, MA
2013
Molecular Pathological Epidemiology: A Paradigm Shift to Address Heterogeneity of Disease
Etiologies and Pathogenesis / Invited Lecture
Society for Epidemiologic Research (SER) Annual Meeting, Boston, MA
2013
Molecular Pathological Epidemiology (MPE): A Paradigm Shift to Address Heterogeneity of
Disease Etiologies for Future Epidemiology / Keynote Lecture
German Society of Epidemiology (DGEpi) Annual Meeting, Leipzig, Germany
2013
Molecular Pathological Epidemiology (MPE): Overview of Its Paradigm and Wide Applicability Even
without Tumor Tissue / Lecturer (and Session Chair)
12th International AACR Frontiers in Cancer Prevention Research Meeting, National Harbor, MD
2013
Tumor Biomarker Discovery for Aspirin Chemoprevention by Molecular Pathological Epidemiology
(MPE) Approach / Lecturer
12th International AACR Frontiers in Cancer Prevention Research Meeting, National Harbor, MD
27
Shuji Ogino, MD, PhD
2/6/2016
2013
Useful and Practical Biostatistics in Molecular Pathology / Lecturer
Association for Molecular Pathology (AMP) Annual Meeting, Phoenix, AZ
2014
Molecular Pathological Epidemiology (MPE): Ubiquitous Population Science / Lecturer and
Discussion Leader
American Society of Preventive Oncology (ASPO) Meeting, Arlington, VA
2014
Power of Molecular Pathological Epidemiology (MPE) Approach to Discover Tumor Biomarkers for
Precision Medicine / Plenary Lecturer
Drug Discovery & Therapy World Congress 2014, Boston, MA
2014
Molecular Pathological Epidemiology (MPE): Integrative Science to Advance Biomedical and
Health Sciences / Plenary Lecturer
EITA Conference on New Media and Biomedical Research, Boston, MA
2014
Molecular Pathological Epidemiology (MPE): Meeting Aims, Opportunities, and Challenges
Opening Lecturer
The Second International Molecular Pathological Epidemiology (MPE) Meeting, Boston, MA
2014
The Second International Molecular Pathological Epidemiology (MPE) Meeting (December 4-5)
Conference Chairperson
2015
"Cancer Epi-NIM (Novelty, Impact, and Mechanism)" Session Chair and Opening Talk
Society for Epidemiologic Research (SER) Annual Meeting, Denver, CO (June 18)
2015
Pharmaco-MPE (Molecular Pathological Epidemiology) Paradigm for Global Precision Medicine
Plenary Lecturer
Drug Discovery & Therapy World Congress 2015, Boston, MA (July 22-25)
2015
Making Sense of Molecular Pathological Epidemiology (MPE) (including Integrative
Immuno-epidemiology)
Lecturer
AACR Integrative Epidemiology Workshop, Boston, MA (Aug 12)
2016
(anticipated) Molecular Pathological Epidemiology (MPE): New Paradigm for Precision
Gastroenterology
Plenary Lecturer and Session Chair
The Japanese Society of Gastroenterology, Tokyo, Japan (April 21-23)
2016
(anticipated) The Third International Molecular Pathological Epidemiology (MPE) Meeting,
Boston, MA (May 12-13)
Conference Chairperson
Report of Clinical Activities and Innovations
Current Licensure and Certifications
1993-
Medical License, Japan
28
Shuji Ogino, MD, PhD
2000200120012003-
2/6/2016
Diplomate in Anatomic Pathology and Clinical Pathology, American Board of Pathology
Diplomate in Molecular Diagnostics, American Board of Clinical Chemistry
Medical License, Commonwealth of Massachusetts
Diplomate in Molecular Genetic Pathology, American Board of Pathology
Practice activities
2001-2004
2004-2007
2004-2007
2007-2010
2011-2012
2012-2013
2013-2014
2014-2015
2015-2016
General Surgical Pathology
General Surgical Pathology
Molecular diagnostics
Molecular diagnostics
Molecular diagnostics
Molecular diagnostics
Molecular diagnostics
Molecular diagnostics
Molecular diagnostics
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
Department of Pathology, BWH
10 weeks per year
8 weeks per year
7 weeks per year
15 weeks per year
10 weeks per year
8 weeks per year
9 weeks per year
10 weeks per year
6 weeks per year
29
Shuji Ogino, MD, PhD
2/6/2016
Clinical Innovations
Bayesian analysis to predict
genetic risks
I have developed a number of new methods of calculating risks. My
methods enable us to calculate genetic risk when genetic testing
results are available in proband or relatives, or test sensitivity varies
among family members. My Bayesian analysis methods have been
useful as cystic fibrosis and spinal muscular atrophy carrier
screening tests have become routine clinical practices.
Standardized nomenclature
system in molecular pathology
reporting for personalized
precision medicine
As an expert in nomenclature of genes and gene variants and
alterations, I have developed standardized molecular pathology
reporting system. In Brigham and Women’s Hospital Center for
Advanced Molecular Diagnostics (CAMD), I have been serving as a
consultant on mutation nomenclature in Oncomap and OncoPanel
tests. Standardized nomenclature system in pathology reports has
become very important as genomic pathology tests are becoming
routine clinical practices. I have played a major role in CAP (College
of American Pathologists) Molecular Oncology Committee, to
standardize molecular testing surveys. I have also played a major
role in AMP (Association for Molecular Pathology) and frequently
given workshops at AMP annual meetings.
Report of Technological and Other Scientific Innovations
Sensitive detection of tumor
somatic mutation by
Pyrosequencing
I have developed molecular assays to detect somatic mutations in
the KRAS, BRAF and PIK3CA genes, which are commonly mutated
in various tumors. The original paper which described KRAS
Pyrosequencing (Ogino et al. J Mol Diagn 2005) has been cited over
350 times. This method has been very popular and widely used
around the world.
Measurement of genomic
DNA methylation in LINE-1
repetitive elements in paraffin
tumor tissue
I have developed an accurate and precise assay to measure LINE-1
methylation level by Pyrosequencing. This is a very simple method
to estimate global DNA methylation level and easily applicable to
archival paraffin tissue.
Establishment of "Molecular
Pathological Epidemiology
(MPE)", the emerging
integrative field of science
Epidemiologic analyses between exposures and molecular changes
in cancer had been performed under the umbrella of molecular
epidemiology, which limited methodological and conceptual
development associated with those analyses. In order to fully
develop this potential groundbreaking area, I established the field of
“Molecular Pathological Epidemiology (MPE)” (Ogino et al. J Natl
Cancer Inst 2010; Ogino et al. Gut 2011; Ogino et al. Nat Rev Clin
Oncol 2011; Ogino et al. Oncogene 2014). I have been advancing
the MPE field as the first “Molecular Pathological Epidemiologist”
(Ogino et al. Am J Epidemiol 2012). Through a unique combination
of expertise in both pathology and epidemiology, my long-term goal
is to transform pathology and epidemiology in an integrative way for
both education and research, towards our goal of personalized
precision medicine and public health.
30
Shuji Ogino, MD, PhD
2/6/2016
Establishment of novel
concepts, the "Unique Tumor
Principle" and the "Unique
Disease Principle"
I established a new concept of "Unique Tumor Principle" (Ogino et
al. Int J Epidemiol 2012; Ogino et al. Expert Rev Mol Diagn 2012),
and more broadly, the "Unique Disease Principle" (Ogino et al. Mod
Pathol 2013). These new concepts have substantial impacts on
personalized precision medicine.
Proposal of "GWAS-MPE
approach"
Genome-wide association studies (GWAS) have shown numerous
risk loci for many different diseases, but GWAS has had little impact
on clinical practice. A major issue in GWAS is that heterogeneous
disease subtypes with differing risk associations are typically lumped
together into one disease entity, which can dilute effect estimates for
risk variants for specific subtypes. MPE design (GWAS-MPE
approach; Ogino et al. Gut 2011) can be used as the next step of
GWAS, to investigate causal mechanisms and refine effect
estimates of risks for specific disease subtypes.
Creation of the "Colorectal
Continuum" Paradigm /
Theory / Concept
The Colorectal Continuum Theory (Yamauchi, Morikawa, et al. Gut
2012; Yamauchi, Lochhead, et al. Gut 2012) underscores the
importance of interplay of gut microbiota, host factors (diet,
immunity, inflammation, etc.), and carcinogenesis.
Gastroenterology research and practice have been based on the
long-standing dogma of proximal vs. distal colorectum. Thus, this
new paradigm which I created has had substantial impacts on
gastroenterology/pathology research and practice.
Establishment of “MPE
Working Group”
To transform pathology and epidemiology by the integrative MPE
field and concept, I recently created the “MPE Working Group”, to
establish standardized methodologies in MPE research and
contribute to personalized medicine. MPE Working Group currently
consists of researchers in the MPE areas mainly based on Harvard
School of Public Health, Brigham and Women’s Hospital, and
Dana-Farber Cancer Institute. As the group leader, I organize
bimonthly MPE Working Group meeting to advance the MPE field.
Establishment of the
“STROBE-MPE” Initiative
Creation of integrative lifecourse MPE model
I initiated "STROBE-MPE" (Ogino et al. Int J Epidemiol, 2012; Ogino
et al. Am J Epidemiol 2012), to establish international guidelines of
MPE research, for personalized medicine and public health.
STROBE stands for “STrengthening of the Reporting of
OBservational Epidemiology” (von Elm et al. PLoS Med 2007), and
is an international guideline for epidemiology research.
Establishment of the
International MPE Meeting
Series
To expand opportunities and address challenges in MPE, I
established the International Molecular Pathological Epidemiology
(MPE) Meeting Series in 2013. Both of the first meeting (April 2013)
and the second meeting (December 2014) were held with success.
The third meeting will be held in Boston on May 12 and 13, 2016.
31
Shuji Ogino, MD, PhD
2/6/2016
Creation of the etiologic field
effect model
The concept of MPE is integrated into the conventional field effect
model to create the novel etiologic field effect model (Lochhead et al.
Mod Pathol 2015). This new model can encompass various
environmental, exogenous and endogenous exposures and somatic
molecular changes as constituents of field effect of carcinogenesis.
Creation of the integrative
lifecourse-MPE model
The concept of MPE is integrated into lifecourse epidemiology to
create the integrative lifecourse-MPE model (Nishi et al. Am J Prev
Med 2015). This new model can address effects of various
exposures during lifecourse of each individual on molecular
pathology of disease, and can possibly help develop strategies of
lifestyle modification and intervention in early life.
32
Shuji Ogino, MD, PhD
2/6/2016
Report of Scholarship
[Current citation h-index = 70. h-index since 2010 = 63. Over 15,500 total citations, including 13,100
citations since 2010]
[I am the first, last or co-last author in 138 (64%) of the 213 research investigation papers and concept
papers together.]
Peer-Reviewed Publications
Research Investigations
1.
Kubo S, Ogino S, Fukushima T, Maruno M, Yoshimine T, Hasegawa H. Immunohistochemical
detection of insulin-like growth factor II (IGF2) in choroid plexus papilloma: a possible marker for
differential diagnosis. Clin Neuropathol 1999;18:74-79.
2.
Ogino S, Cohen ML, Abdul-Karim FW. Atypical teratoid/rhabdoid tumor of the CNS: Cytopathology
and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1,
cathepsin D and Ki-67. Mod Pathol 1999;12:379-385.
3.
Kubo S, Ogino S, Fukushima T, Olson PR, Kida M, Maruno M, Yoshimine T, Hayakawa T.
Immunohistochemical study of insulin-like growth factor II (IGF2) and insulin-like growth factor
binding protein-2 (IGFBP2) in choroid plexus papilloma. Neurol Res 1999;21:339-344.
4.
Ogino S, Redline RW. Villous capillary lesions of the placenta: Distinctions between chorangioma,
chorangiomatosis, and chorangiosis. Hum Pathol 2000;31:945-954.
5.
Ogino S, Kubo S, Abdul-Karim FW, Cohen ML. Comparative immunohistochemical study of
insulin-like growth factor (IGF)-II and IGF receptor type 1 in pediatric brain tumors. Pediatr
Development Pathol 2001;4:23-31.
6.
Ogino S, Leonard DGB, Rennert H, Gao S, Wilson RB. Heteroduplex formation in SMN gene
dosage analysis. J Mol Diagn 2001;3:150-157.
7.
Ogino S, Leonard DGB, Rennert H, Wilson RB. Spinal muscular atrophy genetic testing
experience at an academic medical center. J Mol Diagn 2002;4:53-58.
8.
Ogino S, Leonard DGB, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier
testing for spinal muscular atrophy. Am J Med Genet 2002;110:301-307.
9.
Ogino S, Wilson RB. Quantification of PCR bias caused by a single nucleotide polymorphism in
SMN gene dosage analysis. J Mol Diagn 2002;4:185-190.
10.
Ogino S, Wilson RB. Genotype and haplotype distributions of MTFHR 677C>T and 1298A>C
single nucleotide polymorphisms: A meta-analysis. J Hum Genet 2003;48:1-7.
11.
Ogino S, Gao S, Leonard DGB, Paessler M, Wilson RB. Inverse correlation between SMN1 and
SMN2 copy numbers: Evidence for gene conversion from SMN2 to SMN1. Eur J Hum Genet
2003;11:275-277. (Addendum in 2003;11:723)
33
Shuji Ogino, MD, PhD
2/6/2016
12.
Xu R, Ogino S, Lip V, Fang H, Wu B. Comparison of PCR-RFLP assay with allele-specific PCR in
genetic testing for spinal muscular atrophy. Genet Testing 2003;7:277-281.
13.
Ogino S, Wilson RB, Grody WW. Bayesian risk assessment for autosomal recessive diseases:
fetal echogenic bowel and one or no detectable CFTR mutation. J Med Genet 2004;41:e70.
14.
Ogino S, Wilson RB, Gold B, Hawley P, Grody WW. Bayesian analysis for cystic fibrosis risks in
prenatal and carrier screening. Genet Med 2004;6:439-449.
15.
Khurana JS, Ogino S, Shen T, Parekh H, Scherbel U, DeLong W, Feldman MD, Zhang PJ, Wolfe
H, Alman BA. Bone morphogenetic proteins are expressed by both bone-forming and
non-bone-forming lesions. Arch Pathol Lab Med 2004;128:1267-1269.
16.
Ogino S, Wilson RB, Gold B. New insights on the evolution of the SMN1 and SMN2 genes:
simulation and meta-analysis for allele and haplotype frequency calculations. Eur J Hum Genet
2004;12:1015-1023.
17.
Ogino S, Flodman P, Wilson RB, Gold B, Grody WW. Risk calculations for cystic fibrosis risks in
neonatal screening by immunoreactive trypsinogen and CFTR mutation tests. Genet Med
2005;7:317-327.
18.
Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers
GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by
Pyrosequencing. J Mol Diagn 2005;7:413-421.
19.
Ogino S, Meyerhardt JA, Cantor M, Brahmandam M, Clark JW, Namgyal C, Kawasaki T, Kinsella
K, Michelini AL, Enzinger PC, Kulke MH, Ryan DP, Loda M, Fuchs CS. Molecular alterations in
tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Clin Cancer Res 2005;11:6650-6656.
20.
Ogino S, Brahmandam M, Cantor M, Namgyal C, Kawasaki T, Kirkner G, Meyerhardt JA, Loda M,
Fuchs CS. Distinct molecular features of colorectal carcinoma with signet ring cell component and
colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68.
21.
Ogino S, Kawasaki T, Brahmandam M, Cantor M, Kirkner GJ, Spiegelman D, Makrigiorgos GM,
Weisenberger DJ, Laird PW, Loda M, Fuchs CS. Precision and performance characteristics of
bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J
Mol Diagn 2006;8:209-217.
22.
Ogino S, Cantor M, Kawasaki T, Brahmandam M, Kirkner GJ, Weisenberger DJ, Campan M, Laird
PW, Loda M, Fuchs CS. CpG island methylator phenotype (CIMP) of colorectal cancer is best
characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut
2006;55:1000-1006.
23.
Meyerhardt JA, Heseltine D, Ogino S, Clark JW, Enzinger PC, Ryan DP, Earle CC, Zhu AX, Fuchs
CS. Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase
inhibitor-based chemotherapy in metastatic colorectal cancer. Clin Colorectal Cancer
2006;6:59-65.
34
Shuji Ogino, MD, PhD
2/6/2016
24.
Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Combined analysis of
COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability
and CpG island methylator phenotype in colorectal cancer. Neoplasia 2006;8:458-464.
25.
Ogino S, Brahmandam M, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. Epigenetic profiling of
synchronous colorectal neoplasias by quantitative DNA methylation analysis. Mod Pathol
2006;19:1083-1090.
26.
Ogino S, Odze RD, Kawasaki T, Brahmandam M, Kirkner GJ, Laird PW, Loda M, Fuchs CS.
Correlations of pathologic features with CpG island methylator phenotype (CIMP) by quantitative
DNA methylation analysis in colorectal carcinoma. Am J Surg Pathol 2006;30:1175-1183.
27.
Ogino S, Kawasaki T, Kirkner GJ, Ogawa A, Dorfman I, Loda M, Fuchs CS. Down-regulation of
p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island
methylator phenotype (CIMP) in colorectal cancer. J Pathol 2006;210:147-154.
28.
Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low
(CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol
Diagn 2006;8:582-588.
29.
Priolo C, Tang D, Brahamandan M, Benassi B, Sicinska E, Ogino S, Farsetti A, Porrello A, Finn S,
Zimmermann J, Febbo P, Loda M. The isopeptidase USP2a protects human prostate cancer from
apoptosis. Cancer Res 2006;66:8625-8632.
30.
Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27
(CDKN1B/KIP1) in colorectal cancer is associated with microsatellite instability and CIMP. Mod
Pathol 2007;20:15-22.
31.
Ogino S, Wilson RB, Gold B, Flodman P. Bayesian risk assessment in genetic testing for
autosomal dominant disorders with age-dependent penetrance. J Genet Counsel 2007;16:29-39.
32.
Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Cytoplasmic localization of p27
(cyclin-dependent kinase inhibitor 1B/KIP1) in colorectal cancer: inverse correlations with nuclear
p27 loss, microsatellite instability, and CpG island methylator phenotype. Hum Pathol
2007;38:585-592.
33.
Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated
with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum
Pathol 2007;38:614-620.
34.
Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. Fatty acid synthase
overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG
island methylator phenotype. Hum Pathol 2007;38:842-849.
35.
Meyerhardt JA, Clark JW, Supko J, Eder P, Ogino S, Stewart C, D’Amato F, Dancey J, Enzinger
PC, Zhu A, Ryan DP, Earle C, Mayer R, Kinsella K, Fuchs CS. Phase I study of gefitinib, irinotecan,
5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Cancer Chemotherapy
Pharmacol 2007;60:661-670.
35
Shuji Ogino, MD, PhD
2/6/2016
36.
Ogino S, Kawasaki T, Kirkner GJ, Kraft P, Loda M, Fuchs CS. Evaluation of markers for CpG
island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. J
Mol Diagn 2007;9:305-314.
37.
Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression
of COX-2. N Engl J Med 2007;356:2131-2142. (I am the sole pathologist in this study.)
38.
Ogino S, Kawasaki T, Kirkner GJ, Suemoto Y, Meyerhardt JA, Fuchs CS. Molecular correlates
with MGMT promoter methylation and silencing support CpG island methylator phenotype-low
(CIMP-low) in colorectal cancer. Gut 2007;56:1564-1571.
39.
Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM,
Loda M, Fuchs CS. CpG island methylation, response to combination chemotherapy, and patient
survival in advanced microsatellite stable colorectal carcinoma. Virchows Arch 2007;450:529-537.
40.
Wang F, Wang L, Briggs C, Sicinska E, Gaston SM, Mamon H, Kulke MH, Zamponi R, Loda M,
Maher E, Ogino S, Fuchs CS, Li J, Hader C, Makrigiorgos GM. DNA degradation test predicts
success in whole-genome amplification from diverse clinical samples. J Mol Diagn
2007;9:441-451.
41.
Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in
microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative
(CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 2007;7:72.
42.
Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Dehari R, Meyerhardt JA, Fuchs CS,
Ogino S. Correlation of -catenin localization with cyclooxygenase-2 expression and CpG island
methylator phenotype in colorectal cancer. Neoplasia 2007;9:569-577.
43.
Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y,
Meyerhardt JA, Hunter DJ, Fuchs CS. MGMT germline polymorphism is associated with somatic
MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis
2007;28:1985-1990.
44.
Park DY, Sakamoto H, Kirley SD, Ogino S, Kawasaki T, Kwon E, Mino-Kenudson M, Lauwers GY,
Chung DC, Rueda BR, Zukerberg LR. The Cables gene on chromosome 18q is silenced by
promoter hypermethylation and allelic loss in human colorectal cancer. Am J Pathol
2007;171:1509-1519.
45.
Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. IGFBP3 promoter
methylation in colorectal cancer: relationship with microsatellite instability, CpG island methylator
phenotype and p53. Neoplasia 2007;9:1091-1098.
46.
Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Liu Z, Yamamoto H, Loda M, Fuchs CS, Ogino S.
WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and
CpG island methylator phenotype in colorectal cancer. Mod Pathol 2008;21:150-158.
47.
Kawasaki T, Ohnishi M, Nosho K, Suemoto Y, Kirkner GJ, Meyerhardt JA, Fuchs CS, Ogino S.
CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated
CIMP-high-specific CpG islands, but also low-level methylation at individual loci. Mod Pathol
2008;21:245-255.
36
Shuji Ogino, MD, PhD
2/6/2016
48.
Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, Kirkner GJ, Mino-Kenudson
M, Fuchs CS, Ogino S. Cyclooxygenase-2 overexpression is common in serrated and
non-serrated colorectal adenoma, but uncommon in hyperplastic polyp and sessile serrated
polyp/adenoma. BMC Cancer 2008;8:33.
49.
Ogino S, Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS. LINE-1
hypomethylation is inversely associated with microsatellite instability and CpG island methylator
phenotype in colorectal cancer. Int J Cancer 2008;122:2767-2773.
50.
Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A,
Luikenhuis S, de Cabo R, Fuchs C, Hahn WC, Guarente LP, Sinclair DA. The SIRT1 deacetylase
suppresses intestinal tumorigenesis and colon cancer growth. PLoS ONE 2008;3:e2020.
51.
Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS,
Ogino S. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic
alterations. Neoplasia 2008;10:534-541.
52.
Firestein R, Bass AJ, Kim SY, Ian F. Dunn IF, Silver SJ, Guney I, Freed E, Ligon A, Vena N, Ogino
S, Chheda M, Tamayo P, Finn S, Shrestha Y, Boehm JS, Jain S, Bojarski E, Barretina J, Chan JA,
Baselga J, Tabernero J, Root DE, Fuchs C, Loda M, Shivdasani RA, Meyerson M, Hahn WC.
CDK8 is a colorectal cancer oncogene that regulates -catenin. Nature 2008;455:547-551.
PMCID: PMC2587138
53.
Nosho K, Kawasaki T, Chan AT, Ohnishi M, Suemoto Y, Kirkner GJ, Fuchs CS, Ogino S. Cyclin
D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG
island methylator phenotype. Histopathology 2008;53:588-598.
54.
Schernhammer ES, Ogino S, Fuchs CS. Folate intake and risk of colon cancer in relation to p53
alteration. Gastroenterology 2008;135:770-780.
55.
Schernhammer ES, Giovannucci EL, Fuchs CS, Ogino S. A prospective study of dietary folate and
vitamin B and colon cancer according to MSI and KRAS mutational status. Cancer Epidemiol
Biomarkers Prev 2008;17:2895-2898.
56.
Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, Hazra A, Chan AT, Dehari R,
Giovannucci EL, Fuchs CS. Cyclooxygenase-2 expression is an independent predictor of poor
prognosis in colon cancer. Clin Cancer Res 2008;14:8221-8227.
57.
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, Giovannucci EL,
Fuchs CS. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl
Cancer Inst 2008;100:1734-1738.
58.
Nosho K, Irahara N, Shima K, Kure S, Kirkner GJ, Schernhammer ES, Hazra A, Hunter DJ,
Quackenbush J, Spiegelman D, Giovannucci EL, Fuchs CS, Ogino S. Comprehensive
biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large
population-based sample. PLoS ONE 2008;3:e3698.
59.
Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M,
Fuchs CS. Cohort study of fatty acid synthase expression and patient survival in colon cancer. J
Clin Oncol 2008;26:5713-5720.
37
Shuji Ogino, MD, PhD
2/6/2016
60.
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS.
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in
colon cancer. Gut 2009;58:90-96.
61.
Nosho K, Shima K, Kure S, Irahara N, Baba Y, Chen L, Kirkner GJ, Fuchs CS, Ogino S. JC virus
T-antigen in colorectal cancer Is associated with p53 expression and chromosomal instability,
independent of CpG island methylator phenotype. Neoplasia 2009;11:87-95.
62.
Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, Chan AT, Engelman JA, Kraft P,
Cantley LC, Giovannucci EL, Fuchs CS. PIK3CA mutation is associated with poor prognosis
among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-1484.
63.
Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL,
Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated
receptor- (PPARG, PPARgamma) is associated with good prognosisis. Gastroenterology
2009;136:1242-1250.
64.
Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S.
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer.
Neoplasia 2009;11:418-425.
65.
Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. A cohort
study of p27 localization in colon cancer, body mass index and patient survival. Cancer Epidemiol
Biomarkers Prev 2009;18:1849-1858.
66.
Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A,
Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S. DNMT3B expression might
contribute to CpG island methylator phenotype in colorectal cancer. Clin Cancer Res
2009;15:3663-3671.
67.
Ogino S, Nosho K, Irahara N, Kure S, Shima K, Baba Y, Toyoda S, Chen L, Giovannucci EL,
Meyerhardt JA, Fuchs CS. A cohort study of cyclin D1 expression and prognosis in 602 colon
cancer cases. Clin Cancer Res 2009;15:4431-4438.
68.
Nosho K, Shima K, Irahara N, Kure S, Firestein R, Baba Y, Toyoda S, Chen L, Hazra A,
Giovannucci EL, Fuchs CS, Ogino S. SIRT1 histone deacetylase expression is associated with
microsatellite instability and CpG island methylator phenotype in colorectal cancer. Mod Pathol
2009;22:922-932.
69.
Baba Y, Nosho K, Shima K, Freed E, Irahara N, Philips J, Meyerhardt JA, Hornick JL, Shivdasani
RA, Fuchs CS, Ogino S. Relationship of CDX2 loss with molecular features and prognosis in
colorectal cancer. Clin Cancer Res 2009;15:4665-4673.
70.
Souglakos J, Philips J, Wang R, Marwah S, Silver M, Tzardi M, Silver J, Ogino S, Hooshmand S,
Kwak E, Freed E, Meyerhardt JA, Saridaki Z, Georgoulias V, Finkelstein D, Fuchs CS, Kulke MH,
Shivdasani RA. Prognostic and predictive value of common mutations for treatment response and
survival in patients with metastatic colorectal cancer. Brit J Cancer 2009:101:465-472.
71.
Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA
2009;302:649-658. (I am the sole pathologist in this study)
38
Shuji Ogino, MD, PhD
2/6/2016
72.
Ogino S, Nosho K, Baba Y, Kure S, Shima K, Irahara N, Toyoda S, Chen L, Kirkner GJ, Wolpin BM,
Chan AT, Giovannucci EL, Fuchs CS. A cohort study of STMN1 expression in colorectal cancer:
body mass index and prognosis. Am J Gastroenterol 2009;104:2047-56.
73.
Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Meyerhardt JA, Fuchs CS. Prognostic
significance and molecular associations of 18q loss of heterozygosity: a cohort study of
microsatellite stable colorectal cancers. J Clin Oncol 2009;27:4591-4598.
74.
Meyerhardt JA, Ogino S, Kirkner GJ, Chan AT, Wolpin B, Ng K, Nosho K, Shima K, Giovannucci
EL, Loda M, Fuchs CS. Interaction of molecular markers and physical activity on mortality in
patients with colon cancer. Clin Cancer Res 2009;15:5931-5936.
75.
Ogino S, Nosho K, Shima K, Baba Y, Irahara N, Kirkner GJ, Hazra A, De Vivo I, Giovannucci EL,
Meyerhardt JA, Fuchs CS. p21 expression in colon cancer and modifying effects of patient age and
body mass index on prognosis. Cancer Epidemiol Biomarkers Prev 2009;18:2513-2521.
76.
Worthley DL, Le Leu RK, Whitehall V, Conlon M, Christophersen C, Belobrajdic D, Mallitt K, Hu Y,
Irahara N, Ogino S, Leggett BA, Young GP. A human, double-blind, placebo-controlled,
cross-over trial of prebiotic, probiotic and synbiotic supplementation: effects on luminal,
inflammatory, epigenetic and epithelial biomarkers of colorectal cancer. Am J Clin Nutr
2009;90:578-586.
77.
Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR,
Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to
colorectal cancer is associated with longer survival, independent of lymph node count,
microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res
2009;15:6412-6420.
78.
Kure S, Nosho K, Baba Y, Irahara N, Shima K, Ng K, Meyerhardt JA, Giovannucci EL, Fuchs CS,
Ogino S. Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in
colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2765-2772.
79.
Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL,
Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic
features of synchronous colorectal cancers. Gastroenterology 2009;137:1609-1620.
80.
Ogino S, Meyerhardt JA, Irahara N, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Schaefer P,
Whittom R, Hantel A, Benson III AB, Goldberg RM, Bertagnolli MM, Fuchs CS: for the Cancer and
Leukemia Group B, North Central Cancer Treatment Group, Canadian Cancer Society Research
Institute, Southwest Oncology Group. KRAS mutation in stage III colon cancer and clinical
outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.
81.
Meyerhardt JA, Giovannucci EL, Ogino S, Kirkner GJ, Chan AT, Willett W, Fuchs CS. Physical
activity and male colorectal cancer survival. Arch Int Med 2009;169:2102-2108.
82.
Schernhammer ES, Giovannucci E, Kawasaki T, Rosner B, Fuchs CS, Ogino S. Dietary folate,
alcohol, and B vitamins in relation to LINE-1 hypomethylation in colon cancer. Gut
2010;59:794-799.
39
Shuji Ogino, MD, PhD
2/6/2016
83.
Ogino S, Nosho K, Irahara N, Shima K, Baba Y, Kirkner GJ, Mino-Kenudson M, Giovannucci EL,
Meyerhardt JA, Fuchs CS. Negative lymph node count is associated with survival of colorectal
cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J
Gastroenterol 2010;105:420-433.
84.
Firestein R, Shima K, Nosho K, Irahara N, Baba Y, Bojarski E, Giovannucci EL, Hahn WC, Fuchs
CS, Ogino S. CDK8 expression in 470 colorectal cancers in relation to -catenin activation, other
molecular alterations and patient survival. Int J Cancer 2010;126:2863-2873.
85.
Irahara N, Nosho K, Baba Y, Shima K, Lindeman NI, Hazra A, Schernhammer ES, Hunter DJ,
Fuchs CS, Ogino S. Precision of Pyrosequencing assay to measure LINE-1 methylation in colon
cancer, normal colonic mucosa and peripheral blood cells. J Mol Diagn 2010;12:177-183.
86.
Hazra A, Fuchs CS, Kawasaki T, Kirkner GJ, Hunter DJ, Ogino S. Germline polymorphisms in the
one-carbon metabolism pathway and DNA methylation in colorectal cancer. Cancer Causes
Control 2010;21:331-45.
87.
Irahara N, Baba Y, Nosho K, Shima K, Yan L, Dias-Santagata D, Iafrate AJ, Fuchs CS, Haigis KM,
Ogino S. NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 2010;19:157-163.
88.
Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt K, Le Leu RK,
Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation within the normal colorectal
mucosa is associated with pathway specific predisposition to cancer. Oncogene
2010;29:1653-1662.
89.
Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL,
Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731
colorectal cancers. Am J Pathol 2010;176:2292–2301.
90.
Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS,
Ogino S. PTGER2 overexpression in colorectal cancer is associated with microsatellite instability,
independent of CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev
2010;19:822-831.
91.
Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ,
Giovannucci EL, Fuchs CS, Ogino S. Epigenomic diversity of colorectal cancer indicated by
LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010;9:125.
92.
Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M,
Giovannucci E, Fuchs CS, Ogino S. Prognostic significance of AMP-activated protein kinase
expression and modifying effect of MAPK3/1 in colorectal cancer. Brit J Cancer
2010;103:1025-1033.
93.
Baba Y, Nosho K, Shima K, Huttenhower C, Tanaka N, Hazra A, Giovannucci EL, Fuchs CS,
Ogino S. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite
pyrosequencing, is associated with poor prognosis. Gastroenterology 2010;139:1855-1864.
94.
Tanaka N, Huttenhower C, Nosho K, Baba Y, Shima K, Quackenbush J, Haigis KM, Giovannucci E,
Fuchs CS, Ogino S. Novel application of structural equation modeling to correlation structure
analysis of CpG island methylation in colorectal cancer. Am J Pathol 2010;177: 2731-2740.
40
Shuji Ogino, MD, PhD
2/6/2016
95.
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G,
Fuchs CS, Ogino S. Tumor-infiltrating T-cell subsets, molecular changes in colorectal cancer and
prognosis: cohort study and literature review. J Pathol 2010;222:350-366.
96.
Chan AT, Baba Y, Shima K, Nosho K, Chung DC, Hung KE, Mahmood U, Madden K, Poss K,
Ranieri A, Shue D, Kucherlapati R, Fuchs CS, Ogino S. Cathepsin B expression and survival in
colon cancer: implications for molecular detection of neoplasia. Cancer Epidemiol Biomakers Prev:
2010;19:2777-2785.
97.
Baba Y, Nosho K, Shima K, Hayashi M, Meyerhardt JA, Chan AT, Giovannucci E, Fuchs CS,
Ogino S. Phosphorylated AKT expression is associated with PIK3CA mutation, low stage and
favorable outcome in 717 colorectal cancers. Cancer 2011;117:1399-1408.
98.
Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S.
Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902
colorectal cancers: cohort study and literature review. Int J Cancer 2011;128:1080-1094.
99.
Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt K, Le Leu RK,
Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA methylation in the rectal mucosa is
associated with epithelial proliferation and fecal short-chain fatty acid concentrations. Dig Dis Sci
2011;56:387-396.
100.
Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs
CS, Ogino S. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal
cancers. Cancer Causes Cont 2011;22:301-309.
101.
Chan AT, Ogino S, Giovannucci EL, Fuchs CS. Inflammatory markers are associated with risk of
colorectal cancer and chemopreventative response to anti-inflammatory drugs. Gastroenterology
2011;140(3):799-808.e2.
102.
Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K, Tanaka N, Huttenhower
C, Frank DA, Fuchs CS, Ogino S. STAT3 expression, molecular features, inflammation patterns
and prognosis in a database of 724 colorectal cancers. Clin Cancer Res 2011;17:1452-1462.
103.
Demicco EG, Farris, III, AB, Baba Y, Agbor-Etang B, Bergethon K, Mandal R, Daives D, Fukuoka J,
Shimizu M, Dias-Santagata D, Ogino S, Iafrate AJ, Gaissert HA, Mino-Kenudson M. The
dichotomy in carcinogenesis of the distal esophagus and esophagogastric junction: intestinal-type
vs. cardiac-type mucosa-associated adenocarcinoma. Mod Pathol 2011;24:1177-90.
104.
Mino-Kenudson M, Fernández-del Castillo C, Baba Y, Valsangkar NP, Liss AS, Hsu M,
Correa-Gallego C, Ingkakul T, Johnston RP, Turner BG, Androutsopoulos V, McGrath D, Sahani
DV, Brugge WR, Ogino S, Pitman MB, Warshaw AL, Thayer SP. Prognosis of invasive intraductal
papillary mucinous neoplasm depends on histologic and precursor epithelial subtypes. Gut
2011;60:1712-1720.
105.
Morikawa T, Kuchiba A, Yamauchi M, Meyerhardt JA, Shima K, Nosho K, Chan AT, Giovannucci E,
Fuchs CS, Ogino S. Association of CTNNB1 (β-catenin) alterations, body mass index, and
physical activity with survival in patients with colorectal cancer. JAMA 2011;305:1685-1694.
41
Shuji Ogino, MD, PhD
2/6/2016
106.
Schernhammer ES, Giovannucci E, Baba Y, Fuchs CS, Ogino S. B vitamins, methionine and
alcohol intake and risk of colon cancer in relation to BRAF mutation and CpG island methylator
phenotype (CIMP). PLoS ONE 2011;6:e21102.
107.
Lee JE, Baba Y, Ng K, Giovannucci E, Fuchs C, Ogino S,* Chan AT.* Statin use and colorectal
cancer risk according to molecular subtypes in two large prospective cohort studies. Cancer Prev
Res 2011;4:1808-1815. (* SO and ATC are co-last authors)
108.
Shima K, Morikawa T, Yamauchi M, Kuchiba A, Imamura Y, Liao X, Meyerhardt JA, Fuchs CS,
Ogino S. TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and
prognosis in 1072 colorectal cancers. PLoS ONE 2011;6:e25062.
109.
Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G,
Sivachenko A, Jing R, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E,
Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin Jr WG, Spardy N,
Hahn WC, Hoshida Y, Ogino S, DePinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J,
Tabernero J. Gabriel S, Lander ES, Getz G, Meyerson M. Genomic Sequencing of Colorectal
Adenocarcinomas Identifies a Recurrent VTI1A-TCF7L2 Fusion. Nat Genet 2011;43:964-968.
110.
Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ,
Benson III AB, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP,
Fuchs CS. Relationship between statin use and colon cancer recurrence and survival: results from
CALGB 89803. J Natl Cancer Inst 2011;103:1540-1551.
111.
Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ,
Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS,
Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma.
Genome Res 2012;22:292-298.
112.
Morikawa T, Kuchiba A, Liao X, Imamura Y, Yamauchi M, Qian ZR, Nishihara R, Sato K,
Meyerhardt JA, Fuchs CS, Ogino S. Tumor TP53 expression status, body mass index, and
prognosis in colorectal cancer. Int J Cancer 2012;131:1169-78.
113.
Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, Liao X, Waldron L,
Hoshida Y, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS, Ogino S. Assessment of
colorectal cancer molecular features along bowel subsites challenges the conception of distinct
dichotomy of proximal versus distal colorectum. Gut 2012;61:847-854.
114.
Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X,
Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic significance and molecular
associations of tumor growth pattern in colorectal cancer. Ann Surg Oncol 2012;19:1944-1953.
115.
Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, Meyerhardt JA, Giovannucci E,
Fuchs CS, Ogino S. Body mass index and risk of colorectal cancer according to fatty acid synthase
expression in the Nurses’ Health Study. J Natl Cancer Inst 2012;104:415-420.
116.
Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P,
Whittom R, Hantel A, Benson III AB, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.
Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup
trial CALGB 89803. Clin Cancer Res 2012;18:890-900.
42
Shuji Ogino, MD, PhD
2/6/2016
117.
Morikawa T, Shima K, Kuchiba A, Yamauchi M, Tanaka N, Imamura Y, Liao X, Qian ZR,
Brahmandam M, Longtine JA, Lindeman NI, Fuchs CS, Ogino S. No evidence for interference of
H&E staining in DNA testing: Utility of DNA extraction from H&E-stained archival tissue sections.
Am J Clin Pathol 2012;138:122-129.
118.
Habibollahi P, Figueiredo J, Heidari P, Dulak AM, Imamura Y, Bass AJ, Ogino S, Chan AT,
Mahmood U. Optical imaging with a cathepsin B activated probe for the enhanced detection of
esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics
2012;2:227-234.
119.
Khalili H, Huang ES, Ogino S, Fuchs CS, Chan AT. A prospective study of bisphosphonate use
and risk of colorectal cancer. J Clin Oncol 2012;30:3229-3233.
120.
Morikawa T, Tanaka N, Kuchiba A, Nosho K, Yamauchi M, Hornick JL, Swanson RS, Chan AT,
Meyerhardt JA, Huttenhower C, Schrag D, Fuchs CS, Ogino S. Predictors of lymph node count in
colorectal cancer resections: Data from US nationwide prospective cohort studies. Arch Surg
2012;147:715-723. (Current journal name: JAMA Surgery)
121.
Horst D, Chen J, Morikawa T, Ogino S, Kirchner T, Shivdasani RA. Differential WNT activity in
colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer
Res 2012;72:1547-1556.
122.
Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, Nosho K, Qian ZR,
Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S. Prognostic role of PIK3CA mutation in colorectal
cancer: Cohort study and literature review. Clin Cancer Res 2012;18:2257-2268.
123.
Lin JH, Morikawa T, Chan AT, Kuchiba A, Shima K, Nosho K, Kirkner G, Zhang SM, Manson JA,
Giovannucci E, Fuchs CS, Ogino S. Postmenopausal hormone therapy is associated with a
reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res 2012;72:3020-3028.
124.
Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan
H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer
susceptibility loci and survival time following diagnosis with colorectal cancer. Gastroenterology
2012;143:51-54.e4.
125.
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould
J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo
JA, Golub TR. Tumor microenvironment contributes to innate RAF-inhibitor resistance through
HGF secretion. Nature 2012;487:500-504.
126.
Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R,
Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S. Specific mutations in KRAS codons 12 and 13,
and patient prognosis in 1075 BRAF-wild-type colorectal cancers. Clin Cancer Res
2012;18:4753-4763.
127.
Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu
K, Meyerhardt JA, Fuchs CS, Ogino S. Insulin-like growth factor 2 messenger RNA binding protein
3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer
2012;48:3405-3413.
43
Shuji Ogino, MD, PhD
2/6/2016
128.
Dulak AM, Schumacher S, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos A, Saksena G, Baca
S, Baselga J, Tabernero J, Barretina J, Enzinger P, Corso G, Roviello F, Lin L, Bandla S, Luketich
J, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass
AJ. Gastrointestinal adenocarcinomas of the esophagus, stomach and colon exhibit distinct
patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-4393.
129.
Waldron L*, Ogino S*, Hoshida Y, Shima K, McCart Reed AE, Simpson PT, Baba Y, Nosho K,
Segata N, Vargas AC, Cummings M, Lakhani SR, Kirkner GJ, Giovannucci E, Quackenbush J,
Golub TR, Fuchs CS, Parmigiani G, Huttenhower C. Expression profiling of archival tissues for
long-term health studies. Clin Cancer Res 2012;18:6136-6146. (* Co-first authors)
130.
Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba
Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S.
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med
2012;367:1596-1606.
131.
Bao Y, Giovannucci EL, Kraft P, Stampfer MJ, Ogino S, Ma J, Buring JE, Sesso HD, Lee IM, Rifai
N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A
prospective study of plasma adiponectin and pancreatic cancer risk in 5 U.S. cohorts. J Natl
Cancer Inst 2013;105:95-103.
132.
Ogino S, Nishihara R, Lochhead P, Imamura Y, Kuchiba A, Morikawa T, Yamauchi M, Liao X, Qian
ZR, Sun R, Sato K, Kirkner GJ, Wang M, Spiegelman D, Meyerhardt JA, Schernhammer ES, Chan
AT, Giovannucci E, Fuchs CS. Prospective study of family history and colorectal cancer risk by
tumor LINE-1 methylation level. J Natl Cancer Inst 2013;105:130-140.
133.
Nishihara R, Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, Imamura Y, Nosho K,
Shima K, Kawachi I, Qian ZR, Fuchs CS, Chan AT, Giovannucci E, Ogino S. A prospective study
of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor
classification. Am J Epidemiol 2013;178:84-100.
134.
Garcia-Albeniz X, Nan H, Valeri L, Morikawa T, Kuchiba A, Phipps AI, Hutter CM, Peters U,
Newcomb PA, Fuchs CS, Giovannucci EL, Ogino S*, Chan AT*. Phenotypic and tumor molecular
characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with
survival. Carcinogenesis 2013;34:292-298. (* Co-last authors)
135.
Barry ER, Morikawa T, Butler BL, Shrestha K, de la Rosa R, Yan KS, Fuchs CS, Magness ST,
Smits R, Ogino S, Kuo CJ, Camargo FD. Restriction of intestinal stem cell expansion and the
regenerative response by YAP. Nature 2013;493:106-110.
136.
Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, Liao X, Qian ZR, Ng K,
Chan AT, Meyerhardt JA, Giovannucci E, Fuchs CS, Ogino S. Prospective analysis of body mass
index, physical activity and colorectal cancer risk associated with β-catenin (CTNNB1) status.
Cancer Res 2013;73:1600-1610.
137.
Zhang X, Giovannucci EL, Wu K, Gao X, Hu F, Ogino S, Schernhammer ES, Fuchs CS, Redline S,
Willett WC, Ma J. Associations of self-reported sleep duration and snoring with colorectal cancer
risk in men and women. Sleep 2013;36:681-688.
138.
Phipps AI, Chan AT, Ogino S. Anatomic subsite of primary colorectal cancer and subsequent risk
and distribution of second cancers. Cancer 2013;119:3140-3147.
44
Shuji Ogino, MD, PhD
2/6/2016
139.
Bao Y, Giovannucci E, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring
JE, Sesso H, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin LS, Cochrane BB, Manson JE, Fuchs CS,
Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of 5 U.S.
cohorts. Cancer Epidemiol Biomarkers Prev 2013;22:855-861.
140.
Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. A prospective study of
plasma inflammatory markers and risk of colorectal cancer in men. Brit J Cancer
2013;108:1891-1898.
141.
Yamauchi M, Lochhead P, Imamura Y, Kuchiba A, Liao X, Qian ZR, Nishihara R, Morikawa T,
Shima K, Wu K, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT, Ogino S. Physical activity,
tumor PTGS2 expression, and survival in patients with colorectal cancer. Cancer Epidemiol
Biomarkers Prev 2013;22:1142-1152.
142.
Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y,
Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D,
Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin
L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, Ogino S, Luketich JD, Golub TR, Gabriel
SB, Lander ES, Beer DG, Godfrey TE, Getz G, Bass AJ. Exome and whole genome sequencing of
esophageal adenocarcinoma identified recurrent driver events and mutational complexity. Nat
Genet 2013;45:478-486.
143.
Qian ZR, Ter-Minassian M, Chan JA, Imamura Y, Hooshmand SM, Kuchiba A, Morikawa T, Brais
LK, Daskalova A, Heafield R, Lin X, Christiani DC, Fuchs CS, Ogino S, Kulke MH. Prognostic
significances of MTOR pathway components expression in neuroendocrine tumors. J Clin Oncol
2013;31:3418-3425.
144.
Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso
HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE,
Giovannucci EL, Fuchs CS. Hyperglycemia, insulin resistance, impaired pancreatic β-cell function,
and risk of pancreatic cancer. J Natl Cancer Inst 2013;105:1027-1035.
145.
Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, Imamura Y, Qian ZR, Morikawa T,
Wang M, Spiegelman D, Cho E, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use and
colorectal cancer incidence risk according to BRAF mutation status. JAMA 2013;309:2563-2571.
146.
Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, Inamura K, Kim SA, Kuchiba A,
Yamauchi M, Imamura Y, Willett WC, Rosner BA, Fuchs CS, Giovannucci E, Ogino S*, Chan AT*.
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med
2013;369:1095-1105. (* Co-last authors)
147.
Lochhead P, Kuchiba A, Imamura Y, Liao X, Yamauchi M, Nishihara R, Qian ZR, Morikawa T, Shen
J, Meyerhardt JA, Fuchs CS, Ogino S. Microsatellite instability and BRAF mutation testing in
colorectal cancer prognostication. J Natl Cancer Inst 2013;105:1151-1156.
148.
Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci E, Chan AT. Plasma adiponectin and
soluble leptin receptor and risk of colorectal cancer: A prospective study. Cancer Prev Res
2013;6:875-885.
45
Shuji Ogino, MD, PhD
2/6/2016
149.
Yuan C, Bao Y, Wu C, Kraft P, Ogino S, Ng K, Qian ZR, Rubinson DA, Stampfer MJ, Giovannucci
EL, Fuchs CS, Wolpin BM. Prediagnostic body-mass index and pancreatic cancer survival. J Clin
Oncol 2013;31:4229-4234.
150.
Masuda A, Arisaka Y, Hara S, Matsumoto I, Takenaka M, Sakai A, Shiomi H, Matsuki N, Sugimoto
M, Fujita T, Hayakumo T, Ku Y, Ogino S, Azuma T, Kutsumi H. MUC2 expression and prevalence
of high-grade dysplasia and invasive carcinoma in mixed-type intraductal papillary mucinous
neoplasm of the pancreas. Pancreatology 2013;13:583-588.
151.
Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, Banck MS, Kanwar R,
Kulkarni AA, Karpathakis A, Manzo V, Contractor T, Philips J, Nickerson E, Pho N, Hooshmand
SM, Brais LK, Lawrence MS, Pugh T, McKenna A, Sivachenko A, Cibulskis K, Carter SL, Ojesina
AI, Freeman S, Jones RT, Voet D, Saksena G, Auclair D, Onofrio R, Shefler E, Sougnez C,
Grimsby J, Green L, Lennon N, Meyer T, Caplin M, Chung DC, Beutler AS, Ogino S, Thirlwell C,
Shivdasani R, Asa SL, Harris CR, Getz G, Kulke M, Meyerson M. Somatic mutation of CDKN1B in
small intestinal neuroendocrine tumors. Nat Genet 2013;45:1483-1486.
152.
Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ,
Whittom R, Hantel A, Benson III AB, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM,
Meyerhardt JA, Fuchs CS, for the Alliance for Clinical Trials in Oncology. Predictive and prognostic
analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst
2013;105:1789-1798.
153.
Nan H, Morikawa T, Suuriniemi M, Yu Imamura Y, Werner L, Kuchiba A, Yamauchi M, Hunter DJ,
Kraft P, Giovannucci EL, Fuchs CS, Ogino S, Freedman ML, Chan AT. Aspirin use, 8q24 single
nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J
Natl Cancer Inst 2013;105:1852-1861.
154.
Nimptsch K, Malik VS, Fung TT, Pischon T, Hu FB, Willett WC, Fuchs CS, Ogino S, Chan AT,
Giovannucci E, Wu K. Dietary patterns during high school and risk of colorectal adenoma in a
cohort of middle-aged women. Int J Cancer 2014;134:2458-2467.
155.
Imamura Y, Lochhead P, Yamauchi M, Kuchiba A, Qian ZR, Liao X, Nishihara R, Jung S, Wu K,
Nosho K, Wang YE, Peng S, Bass AJ, Haigis KM, Meyerhardt JA, Chan AT, Fuchs CS, Ogino S.
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and
codon 146 mutations in colorectal cancer: cohort study and literature review. Mol Cancer
2014;13:135.
156.
Cho J, Bass AJ, Lawrence MS, Cibulskis K, Cho A, Lee SN, Yamauchi M, Wagle N, Pochanard P,
Kim N, Park AK, Won J, Hur HS, Greulich H, Ogino S, Sougnez C, Voet D, Tabernero J, Jimenez J,
Baselga J, Gabriel SB, Lander ES, Getz G, Eck MJ, Park WY, Meyerson M. Colon cancer-derived
oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on
asymmetric dimerization and sensitive to cetuximab. Mol Cancer 2014;13:141.
157.
Lezcano C, Lee CW, Larson AR, Menzies AM, Kefford RF, Thompson JF, Mihm MC Jr, Ogino S,
Long GV, Scolyer RA, Murphy GF. Evaluation of stromal HGF immunoreactivity as a biomarker for
melanoma response to RAF inhibitors. Mod Pathol 2014;27:1193-1202.
158.
Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC,
Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W,
Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ,
46
Shuji Ogino, MD, PhD
2/6/2016
Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-driven
tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014;4:452-465.
159.
Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, Fuchs CS, Ogino S,
Giovannucci EL, Chan AT. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15)
and risk of colorectal cancer. J Natl Cancer Inst 2014;106:dju016.
160.
Song M, Chan AT, Fuchs CS, Ogino S, Hu FB, Mozaffarian D, Ma J, Willett WC, Giovannucci EL,
Wu K. Dietary intake of fish, ω-3 and ω-6 fatty acids and risk of colorectal cancer: a prospective
study in U.S. men and women. Int J Cancer 2014;135:2413-2423.
161.
Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, Cho E, Giovannucci E, Fuchs CS*,
Ogino S*, Markowitz SD*, Chan AT*. Aspirin and the risk of colorectal cancer in relation to the
expression of 15-hydroxyprostaglandin dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
(* Co-last authors)
162.
Naito T, Nosho K, Ito M, Igarashi H, Mitsuhashi K, Yoshii S, Aoki H, Nomura M, Sukawa Y,
Yamamoto E, Adachi Y, Takahashi H, Hosokawa M, Fujita M, Takenouchi T, Maruyama R, Suzuki
H, Baba Y, Imai K, Yamamoto H, Ogino S, Shinomura Y. IGF2 DMR hypomethylation in relation to
pathological and molecular features of serrated lesions. World J Gastroenterol
2014:20:10050-10061.
163.
Bezawada N, Song M, Wu K, Mehta RS, Milne G, Ogino S, Fuchs CS, Giovannucci EL, Chan AT.
Urinary prostaglandin metabolites (PGE-M) are associated with risk of colorectal adenomas and
chemopreventive response to anti-inflammatory drugs. Cancer Prev Res 2014;7:758-765.
164.
Sulahian R, Casey F, Shen J, Qian ZR, Shin H, Ogino S, Weir BA, Vazquez F, Liu XS, Hahn WC,
Bass AJ, Chan V, Shivdasani RA. An integrative analysis reveals functional targets of GATA6
transcriptional regulation in gastric cancer. Oncogene 2014;33:5637-5648.
165.
Fuchs MA, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A,
Benson A, Atienza D, Messino M, Kindler H, Venook A, Ogino S, Wu K, Willett WC, Giovannucci
EL, Meyerhardt JA. Sugar-Sweetened Beverage Intake and Cancer Recurrence and Survival in
CALGB 89803 (Alliance). PLoS ONE 2014;9:e99816.
166.
Jung S, Qian ZR, Yamauchi M, Bertrand KA, Fitzgerald KC, Inamura K, Kim SA, Mima K, Sukawa
Y, Zhang X, Wang M, Smith-Warner SA, Wu K, Fuchs CS, Chan AT, Giovannucci EL, Ng K, Cho
E, Ogino S,* Nishihara R. Predicted 25(OH)D score and colorectal cancer risk according to vitamin
D receptor expression. Cancer Epidemiol Biomarkers Prev 2014;23:1628-1637. (* Co-last and
co-corresponding author)
167.
Inamura K, Yamauchi M, Nishihara R, Lochhead P, Qian ZR, Kuchiba A, Kim SA, Mima K, Sukawa
Y, Jung S, Zhang X, Wu K, Cho E, Chan AT, Meyerhardt JA, Harris CC, Fuchs CS, Ogino S.
Tumor LINE-1 methylation level and microsatellite instability in relation to colorectal cancer
prognosis. J Natl Cancer Inst 2014;106:dju195.
168.
Li T, Liao X, Lochhead P, Morikawa T, Yamauchi M, Nishihara R, Inamura K, Kim SA, Mima K,
Sukawa Y, Kuchiba A, Imamura Y, Baba Y, Shima K, Meyerhardt JA, Chan AT, Fuchs CS, Ogino
S*, Qian ZR. SMO expression in colorectal cancer: associations with clinical, pathological and
molecular features. Ann Surg Oncol 2014;21:4164-4173. (* Co-last author)
47
Shuji Ogino, MD, PhD
2/6/2016
169.
Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK,
Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ,
Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S,
Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ,
Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM. Elevated circulating branched chain
amino acids are an early event in pancreatic adenocarcinoma development. Nat Med
2014;20:1193-1198.
170.
Barbie TU, Alexe G, Aref AR, Li S, Zhu Z, Zhang X, Imamura Y, Thai TC, Huang Y, Bowden M,
Herndon J, Cohoon TJ, Fleming T, Tamayo P, Mesirov JP, Ogino S, Wong KK, Ellis MJ, Hahn WC,
Barbie DA, Gillanders WE. Targeting an IKBKE cytokine network impairs triple-negative breast
cancer growth. J Clin Invest 2014;124:5411-5423.
171.
Giannakis M, Hodis E, Mu J, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS,
Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, Ogino S, Fuchs
CS, Garraway LA. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet
2014;46:1264-1266.
172.
Nishihara R, Wang M, Qian ZR, Baba Y, Yamauchi M, Mima K, Sukawa Y, Kim SA, Inamura K,
Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Ogino S*, Schernhammer ES. Alcohol,
one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of
IGF2 differentially methylated region. Am J Clin Nutr 2014;100:1479-1488. (* Co-last and
corresponding author)
173.
Fung TT, Kashambwa R, Sato K, Chiuve SE, Fuchs CS, Wu K, Giovannucci G, Ogino S, Hu FB,
Meyerhardt JA. Post diagnosis diet quality and colorectal cancer survival in women. PLoS ONE
2014;9:e115377.
174.
Ananthakrishnan AN, Du M, Berndt SI, Brenner H, Caan BJ, Casey G, Chang-Claude J, Duggan D,
Fuchs CS, Gallinger S, Giovannucci EL, Harrison TA, Hayes RB, Hoffmeister M, Hopper JL, Hou L,
Hsu L, Jenkins MA, Kraft P, Ma J, Nan H, Newcomb PA, Ogino S, Potter JD, Seminara D, Slattery
ML, Thornquist M, White E, Wu K, Peters U, Chan AT. Red meat intake, NAT2, and risk of
colorectal cancer: A pooled analysis of 11 studies. Cancer Epidemiol Biomarkers Prev
2015;24:198-205.
175.
Inamura K, Yamauchi M, Nishihara R, Kim SA, Mima K, Sukawa Y, Li T, Yasunari M, Zhang X, Wu
K, Meyerhardt JA, Fuchs CS, Harris CC, Qian ZR, Ogino S. Prognostic significance and molecular
features of signet-ring cell and mucinous components in colorectal carcinoma. Ann Surg Oncol
2015;22:1226-1235.
176.
Yuan C, Rubinson DA, Qian ZR, Wu C, Kraft P, Bao Y, Ogino S, Ng K, Clancy TE, Swanson RS,
Gorman MJ, Brais LK, Li T, Stampfer MJ, Hu FB, Giovannucci EL, Kulke MH, Fuchs CS, Wolpin BM.
Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus.
J Clin Oncol 2015;33:29-35.
177.
Song M, Gong J, Giovannucci EL, Berndt SI, Brenner H, Chang-Claude J, Curtis KR, Harrison TA,
Hoffmeister M, Hsu L, Jiao S, Le Marchand L, Potter JD, Schoen RE, Seminara D, Slattery ML,
White E, Wu K, Ogino S, Fuchs CS, Hunter DJ, Tworoger SS, Hu FB, Rimm E, Jensen M, Peters U,
Chan AT. Genetic variants of adiponectin and risk of colorectal cancer. Int J Cancer
2015;137:154-164.
48
Shuji Ogino, MD, PhD
2/6/2016
178.
Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, Saltz LB, Mayer RJ, Benson AB
3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Venook AP, Ogino S, Giovannucci EL,
Fuchs CS. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer
Inst 2015;107:dju345.
179.
Jung S, Je Y, Giovannucci EL, Rosner B, Ogino S, Cho E. Derivation and validation of
homocysteine score in US men and women. J Nutr 2015;145:96-104.
180.
Song M, Nishihara R, Wang M, Chan AT, Qian ZR, Inamura K, Zhang X, Ng K, Kim SA, Mima K,
Sukawa Y, Nosho K, Fuchs CS, Giovannucci EL, Wu K, Ogino S. Plasma 25-hydroxyvitamin D
and colorectal cancer risk according to tumour immunity status. Gut in press.
181.
Song M, Nishihara R, Wu K, Qian ZR, Kim SA, Sukawa Y, Mima K, Inamura K, Masuda A, Yang J,
Fuchs CS, Giovannucci EL, Ogino S,* Chan AT. Marine ω-3 polyunsaturated fatty acids and risk of
colorectal cancer according to microsatellite instability. J Natl Cancer Inst 2015;107:djv007. (*
Co-last and co-corresponding author)
182.
Hsu L, Jeon J, Brenner H, Gruber SB, Schoen RE, Berndt SI, Chan AT, Chang-Clude J, Du M,
Gong J, Harrison TA, Hayes RB, Hoffmeister M, Hutter CM, Lin Y, Nishihara R, Ogino S, Prentice
RL, Schumacher FR, Seminara D, Slattery ML, Thomas DC, Thornquist M, Newcomb PA, Potter
JD, Zheng Y, White E, Peters U, on behalf of the Colorectal Transdisciplinary (CORECT) Study and
Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). A model to determine
colorectal cancer risk using common genetic susceptibility loci. Gastroenterology
2015;148:1330-1339.e14.
183.
Zhang X, Wu K, Giovannucci EL, Ma J, Colditz GA, Fuchs CS, Willett WC, Stampfer MJ, Nimptsch
K, Ogino S, Wei EK. Early life body fatness and risk of colorectal cancer in U.S. women and men results from two large cohort studies. Cancer Epidemiol Biomarkers Prev 2015;24:690-697.
184.
Nan H, Hutter CM, Lin Y, Jacobs EJ, Ulrich CM, White E, Baron JA, Berndt SI, Brenner H,
Butterbach K, Caan BJ, Campbell PT, Carlson CS, Casey G, Chang-Claude J, Chanock SJ,
Cotterchio M, Duggan D, Figueiredo JC, Fuchs CS, Giovannucci EL, Gong J, Haile RW, Harrison
TA, Hayes RB, Hoffmeister M, Hopper JL, Hudson TJ, Jenkins MA, Jiao S, Lindor NM, Lemire M,
Le Marchand L, Newcomb PA, Ogino S, Pflugeisen BM, Potter JD, Qu C, Rosse SA, Rudolph A,
Schoen RE, Schumacher FR, Seminara D, Slattery ML, Thibodeau SN, Thomas F, Thornquist M,
Warnick GS, Zanke BW, Gauderman WJ, Peters U, Hsu L, Chan AT; CCFR and GECCO.
Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants.
JAMA 2015;313:1133-1142.
185.
Gala MK, Austin T, Ogino S, Chan AT. TFF2-CXCR4 axis is associated with BRAF V600E colon
cancer. Cancer Prev Res 2015 (published online).
186.
Song M, Hu FB, Spiegelman D, Chan AT, Wu K, Ogino S, Fuchs CS, Willett WC, Giovannucci EL.
Adulthood weight change and risk of colorectal cancer in the Nurses' Health Study and Health
Professionals Follow-up Study. Cancer Prev Res 2015 (published online).
187.
Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA,
Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E,
Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S.
Fusobacterium nucleatum and T-cells in colorectal carcinoma. JAMA Oncol 2015 (published
online).
49
Shuji Ogino, MD, PhD
2/6/2016
188.
Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, Chan AT, Esko T, Wood AR,
Yang J, Vedantam S, Gustafsson S, Pers TH, GIANT Consortium, Baron JA, Bezieau S, Küry S,
Ogino S, Berndt SI, Casey G, Haile RW, Du M, Harrison TA, Thornquist M, Duggan DJ, Le
Marchand L, Lemire M, Lindor, NM, Seminara D, Song M, Thibodeau SN, Cotterchio M, Win AK,
Jenkins MA, Hopper JL, Ulrich CM, Potter JD, Newcomb PA, Schoen RE, Hoffmeister M, Brenner
H, White E, Hsu L, Campbell PT. Mendelian randomization study of height and risk of colorectal
cancer. Int J Epidemiol 2015 (in press).
189.
Guercio BJ, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A,
Benson A, Atienza D, Messino M, Kindler H, Venook A, Hu FB, Ogino S, Wu K, Willett WC,
Giovannucci EL, Meyerhardt JA, Fuchs CS. Coffee intake, recurrence and mortality in stage III
colon cancer: results from CALGB 89803 (Alliance). J Clin Oncol 2015 (in press).
190.
Tu HC, Schwitalla S, Qian Z, LaPier GS, Yermalovich A, Ku YC, Chen SC, Viswanathan SR, Zhu H,
Nishihara R, Inamura K, Kim SA, Morikawa T, Mima K, Sukawa Y, Yang J, Meredith G, Fuchs
CS, Ogino S, Daley GQ. LIN28 cooperates with WNT signaling to drive invasive intestinal and
colorectal adenocarcinoma in mice and humans. Gene Dev 2015;29:1074-1086.
191.
Thrift AP, Gong J, Peters U, Chang-Claude J, Rudolph A, Slattery ML, Chan AT, Locke AE, Kahali
B, Justice AE, Pers TH, Gallinger S, Hayes RB, Baron JA, Caan BJ, Ogino S, Berndt SI, Chanock
SJ, Casey G, Haile RW, Du M, Harrison TA, Thornquist M, Duggan DJ, Le Marchand L, Lindor NM,
Seminara D, Song M, Wu K, Thibodeau SN, Cotterchio M, Win AK, Jenkins MA, Hopper JL, Ulrich
CM, Potter JD, Newcomb PA, Hoffmeister M, Brenner H, White E, Hsu L, Campbell PT. Mendelian
randomization study of body mass index and colorectal cancer risk. Cancer Epidemiol Biomarkers
Prev 2015 (in press).
192.
Mehta RS, Chong DQ, Song M, Meyerhardt JA, Ng K, Nishihara R, Qian Z, Morikawa T, Wu K,
Giovannucci EL, Fuchs CS, Ogino S,* Chan AT. Association between plasma levels of
macrophage inhibitory cytokine-1 before diagnosis of colorectal cancer and mortality.
Gastroenterology 2015 (in press). (* co-last author)
193.
Khalili H, Gong J, Brenner H, Austin TR, Hutter CM, Baba Y, Baron JA, Berndt SI, Bézieau S, Caan
B, Campbell PT, Chang-Claude J, Chanock SJ, Chen C, Hsu L, Jiao S, Conti DV, Duggan D, Fuchs
CS, Gala M, Gallinger S, Haile RW, Harrison TA, Hayes R, Hazra A, Henderson B, Haiman C,
Hoffmeister M, Hopper JL, Jenkins MA, Kolonel LN, Küry S, LaCroix A, Le Marchand L, Lemire M,
Lindor NM, Ma J, Manson JE, Morikawa T, Nan H, Ng K, Newcomb PA, Nishihara R, Potter JD, Qu
C, Schoen RE, Schumacher FR, Seminara D, Taverna D, Thibodeau S, Wactawski-Wende J,
White E, Wu K, Zanke BW, Casey G, Hudson TJ, Kraft P, Peters U, Slattery ML, Ogino S,* Chan
AT on Behalf of GECCO and CCFR. Identification of a common variant with potential pleiotropic
effect on risk of inflammatory bowel disease and colorectal cancer. Carcinogenesis 2015 in press.
(* co-last and co-corresponding author)
194.
Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, Yang J, Dou R, Masugi Y, Song M,
Kostic AD, Giannakis M, Bullman S, Milner DA, Baba H, Giovannucci EL, Garraway LA, Freeman
GJ, Dranoff G, Garrett WS, Huttenhower C, Meyerson M, Meyerhardt JA, Chan AT, Fuchs CS,
Ogino S. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut (in
press).
Concept Papers (These papers have provided original concepts, paradigms, framework, and models):
50
Shuji Ogino, MD, PhD
2/6/2016
1.
Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA).
Hum Genet 2002;111:477-500. (This paper provided new Bayesian method framework.)
2.
Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn
2008;10:13-27. (This is the first paper to state that each tumor is unique.)
3.
Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the
evolving field of molecular pathological epidemiology. J Natl Cancer Inst 2010;102:365-367. (This
is the first paper to describe "molecular pathological epidemiology (MPE)" as a unique scientific
field.)
4.
Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal
neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut 2011;60:397-411. (This
paper is the first to propose the "GWAS-MPE" approach.)
5.
Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology – integrated analysis of host and
tumor factors for personalized medicine. Nat Rev Clin Oncol 2011:8:711-719. (This paper
conceptualized "immuno-MPE" for the first time, although this "immuno-MPE" term was not used.)
6.
Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, Fuchs CS,
Ogino S. Colorectal cancer: a tale of two sides or a continuum? Gut 2012;61:794-797. (This
paper provided the novel "colorectal continuum model".)
7.
Ogino S, Giovannucci E. Lifestyle factors and colorectal cancer microsatellite instability Molecular pathological epidemiology science, based on unique tumour principle. Int J Epidemiol
2012;41:1072-1074. (This paper provided the "the unique tumor principle", and the
"STROBE-MPE" project idea for the first time.)
8.
Ogino S, King EE, Beck AH, Sherman ME, Milner DA, Giovannucci E. Interdisciplinary education
to integrate pathology and epidemiology: Towards molecular and population-level health science.
Am J Epidemiol 2012;176:659-667. (This paper proposed the integrative MPE education model.)
9.
Ogino S, Beck AH, King EE, Sherman ME, Milner DA, Giovannucci E. Ogino et al. respond to “The
21st century epidemiologist”. Am J Epidemiol 2012;176:672-674. (This paper delineates a
difference between molecular pathological epidemiology (MPE) and molecular epidemiology.)
10.
Ogino S, Fuchs CS, Giovannucci E. How many molecular subtypes? Implications of the unique
tumor principle in personalized medicine. Expert Rev Mol Diagn 2012;12:621-628. (This paper
conceptualized and solidified "the unique tumor principle".)
11.
Ogino S, Lochhead P, Chan AT, Nishihara R, Cho E, Wolpin BM, Meyerhardt AJ, Meissner A,
Schernhammer ES, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of
epigenetics: emerging integrative science to analyze environment, host, and disease. Mod Pathol
2013;26:465-484. (This paper conceptualized "the unique disease principle", which encompasses
"the unique tumor principle".)
12.
Field AE, Camargo Jr CA, Ogino S. The merits of subtyping obesity: one size does not fit all
[viewpoint]. JAMA 2013;310:2147-2148. (This paper extended the MPE concept to obesity
research.)
51
Shuji Ogino, MD, PhD
2/6/2016
13.
Ogino S, Lochhead P, Giovannucci E, Meyerhardt JA, Fuchs CS, Chan AT. Discovery of colorectal
cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular
pathological epidemiology. Oncogene 2014;33:2949-2955. (This paper proposed to build
worldwide MPE databases.)
14.
Lochhead P, Chan AT, Giovannucci E, Fuchs CS, Wu K, Nishihara R, O’Brien M, Ogino S.
Progress and opportunities in molecular pathological epidemiology of colorectal premalignant
lesions. Am J Gastroenterol 2014;109:1205-1214. (This paper applied the MPE concept to
premalignant lesions and molecular pathology during the course of neoplastic progression.)
15.
Lochhead P, Chan AT, Nishihara R, Fuchs CS, Beck AH, Giovannucci E, Ogino S. Etiologic field
effect: reappraisal of the field effect concept in cancer predisposition and progression. Mod Pathol
2015;28:14-29. (This paper conceptualized "the etiologic field effect model", integrating the MPE
paradigm into the conventional field effect model.)
16.
Nishi A, Kawachi I, Koenen KC, Wu K, Nishihara R, Ogino S. Lifecourse epidemiology and
molecular pathological epidemiology [review]. Am J Prev Med 2015;48:116-119. (This paper
provided "the integrative lifecourse - MPE model".)
17.
Wang M, Kuchiba A, Ogino S. A meta-regression method for studying etiologic heterogeneity
across disease subtypes classified by multiple biomarkers. Am J Epidemiol 2015 (in press). (This
paper provided a meta-regression method to analyze multiple biomarkers in MPE research.)
18.
Ogino S, Campbell PT, Nishihara R, Phipps AI, Beck AH, Sherman ME, Chan AT, Troester MA,
Bass AJ, Fitzgerald KC, Irizarry RA, Kelsey KT, Nan H, Peters U, Poole EM, Qian ZR, Tamimi RM,
Tchetgen Tchetgen EJ, Tworoger SS, Zhang X, Giovannucci EL, van den Brandt PA, Rosner BA,
Wang M, Chatterjee N, Begg CB. Proceedings of The Second International Molecular Pathological
Epidemiology (MPE) Meeting. Cancer Causes Cont 2015;26:959-972. (This paper is the first
published proceeding of the International MPE Meeting Series. This also documents the First
International MPE Meeting in 2013.)
19.
Ogino S, Nishihara R, VanderWeele TJ, Wang M, Nishi A, Lochhead P, Qian ZR, Zhang X, Wu K,
Nan H, Yoshida K, Milner DA, Chan AT, Field AE, Camargo CA, Williams MA, Giovannucci EL.
Molecular pathological epidemiology is essential in studying neoplastic and non-neoplastic
diseases in the era of precision medicine. Epidemiology in press. (This paper explains the disease
continuum theory, as well as relevance and applicability of the MPE approach to virtually all
diseases.)
Other Peer-Reviewed Publications:
1.
Ogino S, Ro JY, Redline RW. Malignant rhabdoid tumor. A phenotype? An entity? – A controversy
revisited [review]. Adv Anat Pathol 2000;7:181-190.
2.
Ogino S, Wilson RB. Spinal muscular atrophy: molecular genetics and diagnostics [review].
Expert Rev Mol Diagn 2004;4:15-29.
3.
Ogino S, Wilson RB. Bayesian analysis and risk assessment in genetic testing and counseling
[review]. J Mol Diagn 2004:6:1-9.
4.
Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer [editorial].
52
Shuji Ogino, MD, PhD
2/6/2016
J Natl Cancer Inst 2005;97:1317-1319.
5.
Monzon FA, Ogino S, Hammond ME, Halling KC, Bloom K, Nikiforova MN. The role of KRAS
mutation testing in the management of patients with metastatic colorectal cancer [review].
Arch Pathol Lab Med 2009;133:1600-1606.
6.
The Methylation Working Group of the Association for Molecular Pathology (AMP) Clinical Practice
Committee (Contributing members of the AMP Methylation Working Group: Sepulveda AR, Jones
D, Ogino S, Samowitz W, Gulley ML, Edwards R, Levenson V, Pratt VM, Yang B, Nafa K, Yan L,
Vitazka P). CpG Methylation Analysis - Current Status of Clinical Assays and Potential Applications
in Molecular Diagnostics: A Report of the Association for Molecular Pathology [review].
J Mol Diagn 2009;11:266-278.
7.
Muralidharan K, Wilson RB, Ogino S, Nagan N, Curtis C, Schrijver I. AMP Position Statement on
population carrier screening for Spinal Muscular Atrophy [special article]. J Mol Diagn 2011;13:3-6.
8.
Funkhouser WK, Lubin IM, Monzon FA, Zehnbauer BA, Evans JP, Ogino S, Nowak JA. Relevance,
pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: A report
of the Association for Molecular Pathology. J Mol Diagn 2012;14:91-103.
9.
Rex DK, Ahnen DJ, Baron JA, Batts KP, Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ,
Kalady MF, O'Brien MJ, Odze RD, Ogino S, Parry S, Snover DC, Torlakovic EE, Wise PE, Young J,
Church J. Serrated lesions of the colorectum: review and recommendations from an expert panel.
Am J Gastroenterol 2012;107:1315-1329.
10.
Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti
G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M,
Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C,
Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA,
Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C,
Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P,
Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y,
D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer
classification using the Immunoscore: a worldwide task force [review]. J Transl Med 2012;10:205.
11.
Fuchs CS, Ogino S. Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!
[“Understanding The Pathway” article] J Clin Oncol 2013;31:4358-4361.
12.
Kuller LH, Bracken MB, Ogino S, Prentice RL, Tracy RP. The role of epidemiology in the era of
molecular epidemiology and genomics: Summary of the 2013 AJE-sponsored Society of
Epidemiologic Research Symposium. Am J Epidemiol 2013;178:1350-1354.
13.
Sukawa Y, Ogino S. Molecular pathological Epidemiology (MPE) approach to cancer epigenomics.
Experimental Med 2014;32. (in Japanese)
14.
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A,
Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L,
Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS,
Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P,
Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Ascierto PA,
53
Shuji Ogino, MD, PhD
2/6/2016
Marincola FM, Fox BA, Pagès F. Towards the introduction of the Immunoscore in the classification
of malignant tumors [review]. J Pathol 2014;232:199-209.
15.
Li T, Ogino S, Qian ZR. Toll-like receptor signaling in colorectal cancer: Carcinogenesis to cancer
therapy. World J Gastroenterol 2014;20;17699-17708.
16.
Epplein M, Bostick RM, Mu L, Ogino S, Braithwaite D, Kanetsky PA. Challenges and opportunities
in international molecular cancer prevention research: A report from the ASPO Molecular
Epidemiology and the Environment and International Issues in Cancer Interest Group [meeting
report]. Cancer Epidemiol Biomarkers Prev 2014;23:2613-2617.
Practice Guidelines and Standards:
1.
Rainen L, Arbique JC, Asthana D, Earley MC, Geiszler RL, Krieg-Schneider F, Mannhalter C,
Ogino S, Parish GT, Ballas C, Chandler LJ, Fernandes H, Ferrari M, Lechpammer M, WalkerPeach
CR, Williams LO. Clinical and Laboratory Standards Institute (CLSI) Document MM13-A (Vol 25.
Number 31). Collection, transport, preparation and storage of specimens for molecular methods;
approved guideline. Clincal and Laboratory Standards Institute, Wayne, PA 2005.
2.
Ogino S, Gulley ML, den Dunnen JT, Wilson RB, Association for Molecular Pathology Training and
Education Committee. Standard mutation nomenclature in molecular diagnostics: practical and
educational challenges. J Mol Diagn 2007;9:1-6.
3.
Gulley ML, Braziel RM, Halling KC, Hsi ED, Kant JA, Nikiforova MN, Nowak JA, Ogino S, Oliveira
A, Polesky HF, Silverman L, Tubbs RR, Van Deerlin VM, Vance GH, Versalovic J, for the Molecular
Pathology Resource Committee, College of American Pathologists. Clinical laboratory reports in
molecular pathology. Arch Pathol Lab Med 2007;131:852-863.
4.
Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK,
Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force Report: Evaluating the
Clinical Utility of Tumor Markers in Oncology. J Natl Compr Canc Netw 2011;9:S-1-S-32.
Non-Peer Reviewed Publications:
1.
Ogino S. Spinal muscular atrophy [chapter]. In Encyclopedia of Diagnostic Genomics and
Proteomics, edited by Fuchs J and Podda M. Dekker Publication, New York, NY. 2005.
2.
Ogino S. Spinal muscular atrophy [chapter]. In Encyclopedic Reference of Genomics and
Proteomics in Molecular Medicine, edited by Ganten D and Ruckpaul K. Springer-Verlag,
Heidelberg, Germany. 2006.
3.
Ogino S, Wilson RB. Bayesian analysis [chapter]. In Molecular Pathology in Clinical Practice,
edited by Leonard DG. Springer. 2007.
4.
Hazra A, Ogino S. Epigenomic diversity of colorectal cancer [chapter]. In Epigenomics, edited by
Appasani K. Cambridge University Press 2012.
5.
Wilson RB, Ogino S. Bayesian analysis [chapter]. In Molecular Pathology in Clinical Practice, 2nd
edition, edited by Leonard DG. Springer. 2015.
54
Shuji Ogino, MD, PhD
6.
2/6/2016
Idowu MO, Ogino S. Standard nomenclature: why bother? [chapter]. In Molecular Oncology
Testing For Solid Tumors: A Pragmatic Approach, edited by Idowu MO, Dumur CI, and Garrett CT.
Springer. 2015 (in press).
Letters:
1.
Ogino S. A method to compensate for different amplification efficiencies. J Mol Diagn
2001;3:189-190.
2.
Ogino S, Van Deerlin VMD, Wilson RB. Comment on SMN2-deletion in childhood-onset spinal
muscular atrophy. Am J Med Genet 2002;109:243-244.
3.
Ogino S, Wilson RB. SMN dosage analysis and risk assessment for spinal muscular atrophy. Am
J Hum Genet 2002;70:1596-1598.
4.
Ogino S, Wilson RB. The practice of science at its best. Fertil Steril 2003;80:228-229.
5.
Ogino S, Wilson RB. Importance of the use of standard nomenclature for SMN1 small intragenic
(“subtle”) mutations. Hum Mut 2004;23:392-393.
6.
Chan AT, Ogino S, Fuchs CS. Aspirin, COX-2, and the risk of colorectal cancer: The authors’
reply. New Engl J Med 2007;357:824-825.
7.
Samowitz WS, Ogino S. DNA methylation in breast and colorectal cancers. Mod Pathol
2008;21:1054.
8.
Wilson RB, Ogino S. Carrier frequency of spinal muscular atrophy. Lancet 2008;372:1542.
9.
Chan AT, Ogino S, Fuchs CS. Aspirin use, colorectal cancer survival, and loss to follow-up: The
authors’ reply. JAMA 2009;302:2549-2550.
10.
Ogino S, Meyerhardt JA, Fuchs CS. Reply to Watanabe et al. J Clin Oncol 2010;28:e120.
11.
Nosho K, Ogino S. Reply to letter entitled ‘How dense, how intense? Role of tumour-infiltrating
lymphocytes across colorectal cancer stages’. Re: Nosho et al. Tumour-infiltrating T-cell subsets,
molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol
2010; 222: 350-366. J Pathol 2011;225: 629-630.
12.
Søreide K, Ogino S. Microsatellite instability and retrieval of lymph nodes in stage III colon cancer:
harbinger or hermit? Hum Pathol 2012;43:1785-1786.
13.
Ogino S, Liao X, Chan AT. Aspirin, PIK3CA mutation, and colorectal-cancer survival. N Engl J
Med 2013;368:289-290.
14.
Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl
J Med 2013;369:2355.
.
15.
Nishihara R, Ogino S, Chan AT. Reply. Gastroenterology 2014;147:246-247.
55
Shuji Ogino, MD, PhD
16.
2/6/2016
Lochhead P, Meyerhardt JA, Fuchs CS, Ogino S. Response. J Natl Cancer Inst 2014;106:pii:
dju181.
Case Reports:
1.
Ing EB, Kennerdell JS, Olson PR, Ogino S, Rothfus WE. Solitary fibrous tumor of the orbit. Ophthal
Plast Reconstr Surg 1998;14:57-61.
2.
Ogino S, Al-Kaisi N, Abdul-Karim FW. Cytopathology of oncocytic carcinoid tumor of the lung
mimicking granular cell tumor: a case report. Acta Cytol 2000;44:247-250.
3.
Ogino S, Franks TJ, Deubner H, Koss MN. Thymohemang3iolipoma, a rare histologic variant of
thymolipoma: a case report and review of the literature. Ann Diagn Pathol 2000;4:236-239.
4.
Ogino S, Franks TJ, Yong M, Koss MN. Extensive squamous metaplasia with cytologic atypia in
diffuse alveolar damage mimicking squamous cell carcinoma: a report of 2 cases. Hum Pathol
2002;33:1052-1054.
Thesis
1.
Ogino S. Molecular and Population Genetics of Autosomal Recessive Spinal Muscular Atrophy.
Tokyo, Japan: University of Tokyo Graduate School of Medicine; 2001.
Other Invited Articles: (Article titles in Japanese are translated.)
1.
Ogino S. Getting into a residency in the United States of America. Part I. Igakkai Shimbun (New
Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin,
Tokyo, Japan. 1996; 2186. Vol.11 No.3:13.
2.
Ogino S. Getting into a residency in the United States of America. Part II. Igakkai Shimbun (New
Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin,
Tokyo, Japan. 1996; 2192 Vol.11 No.4:13.
3.
Ogino S. Getting into a residency in the United States of America. Part III. Igakkai Shimbun (New
Medical World Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin,
Tokyo, Japan. 1996; 2199 Vol.11 No.5:12.
4.
Ogino S. As a pathology resident in the United States. Igakkai Shimbun (New Medical World
Weekly). Edition for Medical Students and Residents. (In Japanese). Igaku-Shoin, Tokyo, Japan.
1998; 2277 Vol.13 No.1:14-15.
5.
Ogino S. Pathology residency in the United States: An overview. Byori-to Rinsho (Pathology and
Clinical Medicine). (In Japanese) 1998;16:759-760.
6.
Ogino S. Pathology residency in the United States: Conferences. Byori-to Rinsho (Pathology and
Clinical Medicine). (In Japanese) 1998;16:893.
56
Shuji Ogino, MD, PhD
2/6/2016
7.
Ogino S. Pathology residency in the United States: Surgical pathology. Byori-to Rinsho (Pathology
and Clinical Medicine). (In Japanese) 1998;16:1037-1038.
8.
Ogino S. Pathology residency in the United States: Microscopy training. Byori-to Rinsho
(Pathology and Clinical Medicine). (In Japanese) 1998;16:1181.
9.
Ogino S. Pathology residency in the United States: Autopsy. Byori-to Rinsho (Pathology and
Clinical Medicine). (In Japanese) 1998;16:1351-1352.
10.
Ogino S. Pathology residency in the United States: Board examination and pathologists in the
United States. Byori-to Rinsho (Pathology and Clinical Medicine). (In Japanese). 1998;16:1474.
11.
Ogino S. Postgraduate residency program in pathology in the United States. Gendai Iryo
(Contemporary Medicine). (In Japanese) 1999;31:2410-2413.
12.
Ogino S. The Cooperative Human Tissue Network (CHTN): Its concept and goals. Byori-to Rinsho
(Pathology and Clinical Medicine) (In Japanese) 2000;18:371.
13.
Ogino S. The Cooperative Human Tissue Network (CHTN): Practical issues. Byori-to Rinsho
(Pathology and Clinical Medicine) (In Japanese) 2000;18:571.
14.
Ogino S. Diagnostic molecular pathology in the United States: An update. Byori-to Rinsho
(Pathology and Clinical Medicine) (In Japanese) 2000;18:858.
15.
Ogino S. Quality management in diagnostic molecular pathology. Byori-to Rinsho (Pathology and
Clinical Medicine) (In Japanese) 2000;18:1111-1112.
16.
Ogino S. CAP/ACMG Biochemical and Molecular Genetics Resource Committee and proficiency
testing program in diagnostic molecular pathology. Byori-to Rinsho (Pathology and Clinical
Medicine) (In Japanese) 2000;18:1349.
17.
Ogino S. Education and training in diagnostic molecular pathology at the University of
Pennsylvania. Byori-to Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:202-203.
18.
Ogino S. Pathology board examination in the United States: An update. Byori-to Rinsho
(Pathology and Clinical Medicine) (In Japanese) 2001;19:329.
19.
Ogino S. Educational activities of American Society of Clinical Pathologists (ASCP). Byori-to
Rinsho (Pathology and Clinical Medicine) (In Japanese) 2001;19:434.
20.
Ogino S. Education and training in clinical pathology in the United States. Byori-to Rinsho
(Pathology and Clinical Medicine) (In Japanese) 2001;19:538.
21.
Ogino S. From residency and fellowship to faculty: My experience in the United States (in
Japanese). Medical Research Information Center (MRIC) Mail Magazine 2005 September.
22.
Ogino S. Molecular pathologic epidemiology (molecular epidemiologic pathology): an emerging
field and a new role in cancer prevention (in Japanese). Japanese Researchers’ Academic
Network of Greater Boston (JARAN) Newsletter 2010 January.
57
Shuji Ogino, MD, PhD
2/6/2016
Narrative Report
I am a pathologist with a major research effort and 15-20% clinical effort. I have received major
recognitions as follows: I have received prestigious awards, Ramzi Cotran Young Investigator Award in
2011 from United States and Canadian Academy of Pathology (USCAP); and Executive Officer's Award in
2004 and Meritorious Service Award in 2012 from Association for Molecular Pathology (AMP). In 2014, I
was selected as "the Most Influential Scientific Minds" by Thomson Reuters. I have been elected to
become Member of American Society for Clinical Investigation (ASCI) since 2014. I have also been
serving as a member of FASEB Excellence in Science Award (FASEB standing for Federation of American
Societies for Experimental Biology). In 2015, I received the best Impact Score of 10 in my application for
NCI R35 Outstanding Investigator Award, and obtained 7-year funding support (2015-2022), so that I can
undertake adventurous high-risk high-impact research.
My Area of Excellence is “Investigation”. With unique combined expertise in both molecular pathology
and epidemiology, I have been developing integrative interdisciplinary science of “Molecular Pathological
Epidemiology (MPE)”, which is defined as "epidemiology of molecular pathology and heterogeneity of
disease". I have been conducting MPE research with a particular focus on colorectal cancer. My own
research program has continuously been funded by NIH. Recent highlights of my MPE research include
two studies published in The New England Journal of Medicine (NEJM), which examined colonoscopy
screening and molecular features of colorectal cancer (R Nishihara et al. 2013), and interactive effects of
aspirin and PIK3CA mutation in colorectal cancer (X Liao et al. 2012). The MPE paradigm has
internationally been accepted, and the use of the MPE term has become widespread. I established “The
International MPE Meeting” in 2013, and have been the Chairperson of its Program Committee. “The
Second International MPE Meeting” went very successfully, with 20 expert speakers and over 150
participants from 16 countries and 21 US States, on December 4 and 5 in 2014. In addition to the
establishment of MPE as a distinct field, I have been very innovative in research and have created novel
paradigms, concepts and research framework, such as the “GWAS-MPE Approach” (S Ogino et al. Gut
2011), the “Unique Tumor Principle” (S Ogino et al. Expert Rev Mol Diagn 2012), the “Colorectal
Continuum" model (M Yamauchi et al. Gut 2012), the “Unique Disease Principle” (S Ogino et al. Mod
Pathol 2013), the “Etiologic Field Effect” concept (P Lochhead et al. Mod Pathol 2015), and the lifecourse MPE model (A Nishi et al. Am J Prev Med 2015). I have also been very active in creating new research
collaboration initiatives, including “MPE Working Group”, and “STROBE-MPE Initiative” (S Ogino et al. Am
J Epidemiol 2012). As of August 2015, I have published 194 original articles and 19 concept papers which
have provided novel concepts, paradigms, framework, and ideas. Among those 214 original and concept
papers together, I am the first, last, 2nd last, or co-last author in 138 papers, including those in NEJM
(N=3), JAMA (N=5), JAMA Oncology (N=1), Journal of Clinical Oncology (N=4), Journal of The National
Cancer Institute (N=8), Science Translational Medicine (N=1), Gastroenterology (N=6), Gut (N=9),
American Journal of Gastroenterology (N=3), and Genes & Development (N=1) (all with Impact Factor
>10). As the 3rd last author, I played a major role as a molecular pathologist in two Nature papers (R
Straussman et al. 2012; E Barry et al. 2013) and one Nature Genetics paper (M Giannakis et al. 2014).
With my unique combination of expertise in both molecular pathology and epidemiology, I have been
teaching integration of molecular and population science at Harvard Medical School and affiliated
hospitals, and Harvard T.H. Chan School of Public Health. I have served as a mentor for trainees with a
wide variety of backgrounds in my interdisciplinary research laboratory, including pathologists,
gastroenterologists, surgeons, epidemiologists, nutrition scientists, biostatisticians, and computational
biologists. In addition, I regularly give a lecture for pathology residents and fellows as a part of molecular
diagnostics lecture series.
58
Shuji Ogino, MD, PhD
2/6/2016
As another Significant Supporting Activity, I have been serving as a molecular pathologist, with special
expertise in colorectal cancer molecular tests. As an expert in gene and mutation nomenclature, I have
been playing a major role in clinical molecular tests internationally (eg., for College of American
Pathologists, Association for Molecular Pathology, and National Comprehensive Cancer Network) as well
as locally in routine molecular tests and multi-gene tests such as OncoPanel.
In summary, my research contribution has been very unique in integrating molecular pathology and
population sciences as MPE, and has demonstrated widespread impact on biomedical and public health
sciences. In addition, I am an expert molecular pathologist with effort in clinical service and in teaching and
education, in very unique manners.
59
Download

File - Dr. Ogino Lab - Dana